| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Submission example | IND | — | Subscribe to access the data. | Biologics | Respiratory System | ||
IND Submission example | IND | — | Subscribe to access the data. | Biologics | Respiratory System | ||
IND Submission example | IND | — | Subscribe to access the data. | Biologics | Respiratory System |
Recent Updates
Recently added Catalysts
aTyr Pharma, Inc.$0.54
-0.04 (-6.48%)
D 38Pipeline Score Fair Value Biotech · Clinical
Market Cap
48.05 M
EPS
-0.73
P/E Ratio
-
Value Trade
881.00 K
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
7.32 M
Operating CF
-12.52 M
Total Assets
79.65 M
Total Liabilities
79.65 M
Equity
57.93 M
D/E Ratio
12,345
-15.52 %
Week
-41.31 %
1 Month
-53.33 %
3 Month
-23.77 %
6 Month
-88.96 %
5 Year
-99.98 %
All Time
Cash Data
Cash Position
66.51 M
Monthly Burn
4.17 M
Runway
14.3 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
1.40 M
52 Week Range
0.40 - 7.29
% held by Insiders
2.59 %
% held by Institutions
46.16 %
Enterprise Value
-6.96 M
Total Shares
98.00 M
Short %
15.04 %
Float Shares
96.43 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for aTyr Pharma, Inc.
619Total events
2Upcoming
83Tier-1 (high impact)
2016 – 2026Coverage
Upcoming catalysts 2
Event history 617
Jun 14, 2026
●Poster PresentationATYR0101Presentation
Poster presentation on ATYR0101 at Extracellular Matrix Pharmacology Congress
fibrosissource ↗
Jun 4, 2026
Jun 2026
●IND SubmissionefzofitimodIND
IND submission for new Phase 3 study in pulmonary sarcoidosis
pulmonary sarcoidosissource ↗
Jun 2026
●Type C MeetingefzofitimodFDA Meeting
FDA Type C Meeting to inform future efzofitimod development
pulmonary sarcoidosissource ↗
Jun 2026
●Trial InitiationefzofitimodTrial
EFZO-CONNECT Phase 2 trial in SSc-ILD advancing
systemic sclerosis-associated interstitial lung disease (SSc-ILD)source ↗
Jun 2026
May 20, 2026
◆Oral PresentationPresentation
RBC Capital Markets Global Healthcare Conference 1x1 Investor Meetings
May 15, 2026
◆Type C MeetingefzofitimodFDA Meeting
Type C meeting with FDA to review Phase 3 EFZO-FIT results and determine path forward
pulmonary sarcoidosissource ↗
May 11, 2026
◆Type C MeetingefzofitimodFDA Meeting
FDA Type C meeting to review Phase 3 EFZO-FIT study results and determine next steps
pulmonary sarcoidosissource ↗
May 11, 2026
●Oral PresentationPresentation
Conference call and webcast to discuss regulatory and clinical update
Drug Pipeline Intelligence
D38
Pipeline Score $61M
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored1.3x
rNPV / MCap Top 54%
Micro Cap (rank 420 of 911)
Percentile RankaTyr Pharma, Inc. faces pipeline headwinds (38/100), with $955M risk-adjusted pipeline value, led by Efzofitimod /kg in Pulmonary Sarcoidosis (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Efzofitimod /kg Small molecule | Pulmonary Sarcoidosis | Phase 3 | NCT05415137 | 50% | $938M | COMPLETED | 268 | SLOW | B (76) | Jul 14, 2025 | LOW_RISK | MEDIUM Jul 5, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
efzofitimod | pulmonary sarcoidosis | Phase 3 | 2026-03-05 | 268 patients; 3.0 mg/kg and 5.0 mg/kg; did not meet its primary endpoint; p=0.0479; p=0.0226; p=0.0197; p=0.0196 Read More | Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update Company scheduled to meet Read More | |
efzofitimod | pulmonary sarcoidosis | Phase 3 | 2026-03-05 | 268 patients; 3.0 mg/kg and 5.0 mg/kg; did not meet its primary endpoint; p=0.0479; p=0.0226; p=0.0197; p=0.0196 Read More | Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update Company scheduled to meet Read More | |
efzofitimod | pulmonary sarcoidosis | Phase 3 | 2026-03-05 | 268 patients; 3.0 mg/kg and 5.0 mg/kg; did not meet its primary endpoint; p=0.0479; p=0.0226; p=0.0197; p=0.0196 Read More | Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update Company scheduled to meet Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ATYR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ATYR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ATYRNatural Asp-tRNA Synthetase Fragment Interacts with LTBP-1 on the ECM Promoting Myofibroblast Apoptosis and Reducing Fibrosis
The article discusses the interaction of a natural Asp-tRNA synthetase fragment with LTBP-1 on the extracellular matrix, which promotes myofibroblast apoptosis and reduces fibrosis. This research is relevant to understanding potential therapeutic approaches for conditions like pulmonary sarcoidosis and systemic sclerosis-associated interstitial lung disease. The focus is on the implications of this interaction in fibrotic diseases.
Read more →ATYRForward-Looking Statements The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal secur
aTyr Pharma has made strides in advancing efzofitimod, an immunomodulator targeting pulmonary sarcoidosis, while acknowledging risks in forward-looking statements. The recent EFZO-FIT study involved the largest cohort ever in this area but did not meet its primary endpoint. However, findings suggest that patients can manage symptoms on lower doses of corticosteroids without worsening disease. The company is focusing on addressing the significant unmet medical need in this orphan disease with no FDA-approved therapies for over 70 years.
Read more →ATYR▼ -10%on this news
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
aTyr Pharma has announced its first quarter 2026 results, highlighting continued development of efzofitimod for pulmonary sarcoidosis after a positive FDA Type C meeting. The company plans to submit an IND application in June 2026 for a new Phase 3 study targeting chronic symptomatic pulmonary sarcoidosis. Furthermore, aTyr is on track to complete enrollment in a Phase 2 study for systemic sclerosis-related interstitial lung disease within the first half of 2026. The financial outlook shows a healthy cash position of $68.3 million.
Read more →ATYR▼ -10%on this news
Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update Company to continue development of efzofi
aTyr Pharma announced its first quarter 2026 results, highlighting continued development of efzofitimod for pulmonary sarcoidosis after a Type C meeting with the FDA. The company plans to file an IND in June 2026 for a Phase 3 study targeting chronic, symptomatic patients. Additionally, they are on track to complete enrollment in a Phase 2 study focused on systemic sclerosis-related interstitial lung disease by the first half of 2026, with a solid financial position of $68.3 million reported at the end of Q1 2026.
Read more →ATYR▼ -25.3%on this newsshared move
aTyr Pharma to Participate in Upcoming Investor Conferences
aTyr Pharma, Inc. will be participating in two investor conferences in May and June 2026, aimed at enhancing investor relations. The conferences are the RBC Capital Markets Global Healthcare Conference and the Jefferies Global Healthcare Conference, where company management, including President and CEO Sanjay S. Shukla, will engage with investors through presentations and one-on-one meetings. aTyr focuses on developing first-in-class therapies using its unique tRNA synthetase platform for conditions like interstitial lung disease.
Read more →ATYRaTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting
aTyr Pharma has outlined its plans for efzofitimod in pulmonary sarcoidosis following positive feedback from the FDA. The company aims to submit an IND application in June 2026 for a new Phase 3 study focusing on patients with restrictive lung disease. Key endpoints will include forced vital capacity (FVC) and the King's Sarcoidosis Questionnaire (KSQ)-Lung score. Management expressed confidence in the drug's safety and efficacy, while adjusting the dosing schedule to improve patient outcomes.
Read more →ATYR▼ -6.4%on this news
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
aTyr Pharma released its financial and operational update for 2025, highlighting the results from its Phase 3 EFZO-FIT™ study for efzofitimod in pulmonary sarcoidosis. The study marked a significant milestone for the company, even as it fell short of its primary efficacy endpoint. The company has scheduled a Type C meeting with the FDA to discuss the study's results and next steps, while also progressing with enrollment in its Phase 2 EFZO-CONNECT™ study for systemic sclerosis-related interstitial lung disease. aTyr ended the year with substantial cash reserves of $80.9 million.
Read more →ATYR▼ -6.4%on this news
Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update Company scheduled to meet
aTyr Pharma has announced its fourth quarter and full year 2025 results, highlighting progress in the development of efzofitimod for interstitial lung disease. The company is scheduled to meet with the FDA in mid-April 2026 to discuss the results of its Phase 3 EFZO-FIT study in pulmonary sarcoidosis. Although the study did not meet its primary endpoint, clinical benefits were observed, and additional studies in systemic sclerosis-related ILD are on track for completion. aTyr ended the year with a solid cash position of $80.9 million, supporting its ongoing research efforts.
Read more →ATYRBrandon Yaras
Brandon Yaras has been appointed as Vice President of Finance at aTyr since May 2022. He brings nearly 20 years of experience in corporate finance and accounting, having previously worked at Arrowhead Pharmaceuticals and Tutor Perini Corporation. Yaras is a Certified Public Accountant and holds a B.A. from UCLA.
Read more →ATYRaTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma has announced the granting of nonstatutory stock options to two new employees, totaling 12,200 shares, as part of its inducement plan under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $0.98 per share, matching the closing price on February 17, 2026. Each option will vest over four years, encouraging long-term employment. aTyr continues to focus on leveraging its tRNA synthetase platform for the development of novel therapies, including its lead candidate, efzofitimod, for interstitial lung disease.
Read more →ATYR▲ +5.6%on this newsshared move
A Bispecific Antibody Designed to Act as a NRP2/PLXNA1 Agonist Mimics Anticancer Activity of SEMA3F
The article discusses a bispecific antibody developed by aTyr that acts as a NRP2/PLXNA1 agonist, mimicking the anticancer activity of SEMA3F. This innovation could lead to new therapeutic avenues in cancer treatment. The potential efficacy of this approach is highlighted, showcasing its relevance in the ongoing battle against cancer.
Read more →ATYRaTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
aTyr Pharma, a clinical stage biotechnology company, will present at the Leerink Partners Global Healthcare Conference from March 8-11, 2026, in Miami, FL. CEO Sanjay S. Shukla will lead the presentation on the company's advancements in tRNA synthetase-based therapies. Investors can also schedule one-on-one meetings with the management team. A webcast of the presentation will be available on their website.
Read more →ATYRSubcutaneous Delivery of a Natural Asp-tRNA Synthetase Fragment Targeting Myofibroblasts Shows Strong Exposure and Reduced Markers of Lung Inflammation
The article discusses the promising results of a study on a natural Asp-tRNA synthetase fragment that targets myofibroblasts. The study highlights strong exposure following subcutaneous delivery and a reduction in lung inflammation markers. These findings suggest potential therapeutic benefits for conditions like pulmonary sarcoidosis and SSc-ILD.
Read more →ATYRaTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis
aTyr Pharma announced a Type C meeting with the FDA scheduled for mid-April 2026 to discuss the efzofitimod program for pulmonary sarcoidosis. The Phase 3 EFZO-FIT study showed clinical benefits despite not meeting its primary endpoint. The company aims to determine the next steps for efzofitimod following the meeting.
Read more →ATYRATYR DEADLINE ALERT: Hagens Berman Alerts aTyr Pharma (ATYR) Investors of Today’s Lead Plaintiff Deadline in Securities Class Action
Hagens Berman reported a deadline for a class action lawsuit against aTyr Pharma due to allegations of misleading information regarding its drug, Efzofitimod. Following a significant failure in a clinical trial, aTyr's stock plummeted by 83.2%, leading to investor losses. The lawsuit claims the company concealed adverse facts that could have impacted stock prices and investor decisions. The firm is encouraging affected investors to come forward as they investigate potential legal violations by the company and its executives.
Read more →ATYRATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has initiated a class action lawsuit against aTyr Pharma, Inc., claiming securities fraud violations related to false statements made during a specified class period. The lawsuit alleges that aTyr misrepresented the efficacy of its drug, Efzofitimod, and concealed important information regarding its forced taper study design. Investors who purchased the company's securities during this period and incurred losses are encouraged to participate in the lawsuit. The class has yet to be certified, meaning affected investors are currently not represented by an attorney unless they take action.
Read more →ATYRATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure
Hagens Berman, a global plaintiffs’ rights law firm, has urged investors in aTyr Pharma, Inc. to take action in response to a securities class action lawsuit stemming from a substantial stock price drop. The lawsuit was triggered by the failure of aTyr's drug trial for Efzofitimod, which did not meet its primary endpoint, causing an 83% decrease in stock value. Allegations indicate that the company may have misled investors regarding the drug's efficacy and its potential market impact. Investors who purchased shares during the specified class period are encouraged to submit their losses before the December 8, 2025, deadline.
Read more →ATYRaTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR
DJS Law Group has announced a class action lawsuit against aTyr Pharma, Inc. for purported violations of U.S. securities law. The lawsuit claims that aTyr made false and misleading statements regarding the efficacy of its drug candidate, Efzofitimod, during the class period from January 16, 2025, to September 12, 2025. Shareholders affected by these statements are encouraged to contact DJS Law Group, as lead plaintiff status is not a prerequisite for participation in any recovery. The deadline for joining the suit is December 8, 2025.
Read more →ATYRATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
A class action lawsuit has been filed against aTyr Pharma, Inc. following allegations of securities law violations by the company and certain executives. The lawsuit claims that the defendants made misleading statements about the drug Efzofitimod, falsely portraying its efficacy and downplaying risks associated with stopping steroid use. Investors who suffered losses during the defined 'Class Period' are urged to join the lawsuit. The firm representing the investors typically operates on a contingency fee basis, meaning they only collect fees if the case is won.
Read more →ATYRATYR DEADLINE MONDAY: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages aTyr Pharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important December 8 Deadline in Securities Class Action - ATYR
Rosen Law Firm is urging investors of aTyr Pharma, Inc. to secure counsel before the important December 8 deadline related to a securities class action. The lawsuit claims that aTyr misled investors about the efficacy of its drug, Efzofitimod, causing financial damages when the true situation was revealed. Investors who purchased stock during the specified Class Period are eligible for compensation without upfront fees. The Rosen Law Firm emphasizes the importance of choosing qualified legal representation, as many firms offering similar services may lack proper experience.
Read more →ATYR▲ +9.3%on this newsshared move
ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Faruqi & Faruqi, LLP has initiated an investigation into aTyr Pharma, Inc. regarding potential violations of federal securities laws. The investigation stems from claims that aTyr and its executives made misleading statements about the drug efzofitimod, particularly regarding its ability to allow patients to taper off steroid usage. Following the release of unfavorable results from the EFZO-FIT study, aTyr's stock plummeted by 83.25%, prompting investor concerns. The firm is urging affected investors to discuss their legal options before the December 8, 2025, deadline to join a federal class-action lawsuit.
Read more →ATYR▼ -5%on this newsshared move
ATYR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR
Rosen Law Firm has announced an important deadline of December 8, 2025, for a lead plaintiff in a class action lawsuit concerning aTyr Pharma, Inc. Investors who purchased ATYR common stock from January 16, 2025, to September 12, 2025, may be eligible for compensation. The lawsuit alleges that the company made misleading statements about the efficacy of its drug, Efzofitimod, particularly regarding steroid usage tapering. Potential class members are encouraged to select experienced legal counsel to represent them in the case.
Read more →ATYRaTyr Pharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 8, 2025 to Discuss Your Rights – ATYR
Levi & Korsinsky, LLP has initiated a class action lawsuit against aTyr Pharma, Inc. for alleged securities fraud affecting investors between November 7, 2024, and September 12, 2025. The complaint claims the company made misleading statements about the effectiveness of its drug, Efzofitimod, particularly related to steroid tapering. The lawsuit follows the disclosure that aTyr's EFZO-FIT study did not meet its primary endpoint, leading to a severe decline in share price. Investors have until December 8, 2025, to apply as lead plaintiff in the case.
Read more →ATYR▲ +17%on this newsshared move
aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug’s Efficacy Moves Forward -- Hagens Berman
aTyr Pharma (NASDAQ: ATYR) has reported a wider-than-expected loss for the third quarter, missing Wall Street estimates amid ongoing and escalating legal challenges. Their GAAP EPS loss reached -$0.26, driven by disappointing clinical trial results from the Phase 3 EFZO-FIT study, which did not meet its primary endpoint. The company is now also facing securities class action suits alleging misleading statements regarding the efficacy of their lead drug, efzofitimod. Despite these challenges, management indicates a commitment to meeting with the FDA in early 2026 to explore future opportunities for the drug.
Read more →ATYRDarin Lee, Ph.D.
Darin Lee, Ph.D., has been appointed Vice President of Technical Operations at aTyr since November 2025. With over 20 years of experience in the biopharmaceutical sector, he has contributed significantly to CMC and biologics development. His previous roles include overseeing CDMO management and authoring key regulatory documents.
Read more →ATYR▼ -9.7%on this newsshared move
aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged – Hagens Berman
A new class action lawsuit has been filed against aTyr Pharma, Inc. (ATYR) following a failed clinical trial for its drug Efzofitimod. The lawsuit claims that the company made false statements regarding the drug's efficacy, leading to inflated stock prices. As the class period has been expanded to include earlier investors, the firm's actions may have broader legal implications. Following the public announcement that the drug trial did not meet its primary endpoint, aTyr's stock experienced a drastic decline of 83.2% in one day.
Read more →ATYR▲ +5.6%on this newsshared move
aTyr Pharma, Inc. Class Action: Levi & Korsinsky Reminds aTyr Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 8, 2025 – ATYR
Levi & Korsinsky, LLP has notified investors of a class action lawsuit against aTyr Pharma, Inc. (NASDAQ: ATYR) due to alleged securities fraud occurring between November 7, 2024, and September 12, 2025. The lawsuit aims to recover losses incurred by investors who were misled by positive statements regarding the efficacy of Efzofitimod, which reportedly did not meet its primary endpoint during clinical trials. Following the announcement of disappointing results, aTyr's stock plummeted by 83.2%. Investors have until December 8, 2025, to request lead plaintiff status in the lawsuit, although sharing in any compensation does not require this position.
Read more →ATYR▲ +5.6%on this newsshared move
ATYR SHAREHOLDER ALERT: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman
A new class action lawsuit has been initiated against aTyr Pharma, Inc., encompassing an expanded class period for investors who faced significant losses following misleading claims about the drug Efzofitimod. This complaint accuses the company and its executives of securities law violations, asserting that they provided overly optimistic statements about the drug's clinical efficacy. Notably, aTyr's stock suffered an abrupt decline of 83.2% after the failure to meet primary endpoints in a key clinical trial. Hagens Berman, the firm leading the investigation, is scrutinizing the company's previous representations regarding the drug's effectiveness.
Read more →ATYR▼ -8.2%on this newsshared move
ATYR Investors: Securities Law Firm Robbins LLP Reminds Investors of the Pending Lead Plaintiff Deadline in the Class Action Against aTyr Pharma, Inc.
Robbins LLP has announced a reminder for aTyr Pharma, Inc. shareholders about the upcoming lead plaintiff deadline in a class action lawsuit. The lawsuit alleges that aTyr misled investors regarding the effectiveness of its intravenous drug candidate, Efzofitimod, during a clinical trial. The trial reportedly failed to meet its primary endpoint, resulting in a significant drop in the company's stock price. Shareholders considering participation in the class action must submit their papers by December 8, 2025.
Read more →ATYR▼ -8.2%on this newsshared move
ATYR Investor Alert: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman
A class action lawsuit has been filed against aTyr Pharma, Inc. by the firm Hagens Berman, significantly expanding the class period to encompass losses incurred by investors between November 2024 and September 2025. The lawsuit alleges that the company and its executives misrepresented the efficacy of their drug, Efzofitimod, during clinical trials. This comes after the announcement that the EFZO-FIT study failed to meet its primary endpoint, resulting in a drastic 83.2% decline in stock price. Investors who suffered losses are being urged to come forward and participate in the lawsuit.
Read more →ATYRaTyr Pharma, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before December 8, 2025 to Discuss Your Rights – ATYR
aTyr Pharma, Inc. is involved in a class action securities lawsuit filed by Levi & Korsinsky, LLP, which seeks to recover losses for investors affected by alleged securities fraud between November 2024 and September 2025. The lawsuit highlights false statements made by the company regarding the efficacy of their drug Efzofitimod, particularly related to tapering steroid use. The issue escalated after the EFZO-FIT study did not meet its primary endpoint, causing the company’s stock to drop sharply from $6.03 to $1.02 over a two-day period. Investors have until December 8, 2025, to join the lawsuit and potentially seek compensation.
Read more →ATYRaTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference
aTyr Pharma will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. CEO Sanjay S. Shukla will lead the presentation, which will be available via webcast. The company is focused on developing therapies from its tRNA synthetase platform, particularly for interstitial lung disease.
Read more →ATYRATYR LAWSUIT ALERT: The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
A class action lawsuit has been filed against aTyr Pharma, Inc. following disappointing results from the EFZO-FIT study, which did not meet its primary endpoint. The decline in stock price, from $6.03 to $1.02, resulted in an 83.2% drop after the announcement revealed misleading statements about the drug Efzofitimod's efficacy. Shareholders who purchased stock during the defined class period are being notified to participate in the lawsuit. The deadline for registering as a lead plaintiff is set for December 8, 2025.
Read more →ATYRATYR Investor Alert: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged – Hagens Berman
A new class action lawsuit has been filed against aTyr Pharma, Inc. that significantly enlarges the alleged class period for investors. The lawsuit claims that aTyr and its executives provided misleading information about the efficacy of their drug, Efzofitimod, particularly in a critical Phase 3 study. Following disappointing results that failed to meet primary endpoints, aTyr's stock experienced a dramatic drop. Prominent shareholders rights firm Hagens Berman is now investigating the alleged misrepresentations and their impact on investors.
Read more →ATYRATYR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Announces that aTyr Pharma Investors Have Opportunity to Lead Class Action Lawsuit
Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, encouraging investors who experienced losses from January 16 to September 12, 2025, to consider participating in a class action lawsuit. The firm alleges that aTyr misled investors about the efficacy of its drug, efzofitimod, while a significant decrease in stock price occurred after the release of disappointing clinical trial results. A court deadline for stakeholders to seek lead plaintiff status is set for December 8, 2025. The law firm is open to information from anyone related to aTyr's actions.
Read more →ATYR▲ +6%on this newsshared move
Advancing a Therapeutic Platform Based on tRNA Synthetases for Treatment of Fibrotic Lung Diseases
aTyr Pharma is advancing a therapeutic platform based on tRNA synthetases aimed at treating fibrotic lung diseases, including pulmonary sarcoidosis. The company is focused on its lead candidate, Efzofitimod, and has established research programs to support its development. This innovative approach may enhance treatment options for patients suffering from these conditions.
Read more →ATYR▲ +6%on this newsshared move
aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged -- Hagens Berman
aTyr Pharma, Inc. faces a new class action lawsuit filed by Hagens Berman, significantly widening the alleged class period for investors who suffered losses due to misleading statements regarding the efficacy of its drug, Efzofitimod. The litigation claims the company concealed adverse facts during the Phase 3 trial, leading to inflated stock prices. Following the announcement that the drug did not meet its primary endpoint, aTyr's stock plummeted dramatically. The firm is now investigating the extent of the company's alleged misrepresentations.
Read more →ATYR▲ +6%on this newsshared move
aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update
aTyr Pharma reported its third quarter 2025 results, highlighting the Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Although the primary endpoint was not achieved, the therapy showed potential benefits in improving patient quality of life. The company plans to consult with the FDA in early 2026 to discuss next steps for efzofitimod.
Read more →ATYR▼ -5.3%on this newsshared move
Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update Results reported for Phase 3 EFZO-FIT stu
aTyr Pharma announced its third-quarter results for 2025, focusing on the Phase 3 EFZO-FIT study of efzofitimod, which, despite not meeting its primary endpoint, demonstrated improvements in quality of life for patients with pulmonary sarcoidosis. The company plans to consult the FDA in early 2026 regarding the future development of efzofitimod. Additionally, enrollment for the Phase 2 EFZO-CONNECT study is expected to complete in the first half of 2026. The company ended the quarter with a robust cash position of $92.9 million.
Read more →ATYR▼ -6.1%on this newsshared move
ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ATyr Pharma
Faruqi & Faruqi, LLP is investigating claims on behalf of investors in ATyr Pharma, alleging violations of federal securities laws. The investigation stems from claims that ATyr misled investors regarding the effectiveness of its lead drug, Efzofitimod, particularly in terms of its capabilities related to steroid tapering. Following the release of trial data indicating minimal benefit from the drug, ATyr's stock experienced a significant decline of 83.25%. Investors who suffered losses of over $10,000 are being encouraged to consider their legal options.
Read more →ATYRATYR Shareholder Alert: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman
A new class action complaint has been initiated against aTyr Pharma, expanding the period covered by ongoing securities litigation to include investors who acquired shares from November 7, 2024, to September 12, 2025. The suit alleges that aTyr misrepresented the efficacy of its drug Efzofitimod, which was evaluated in a pivotal Phase 3 clinical trial. Following the disappointing trial results, which revealed that the drug did not meet its primary endpoint, aTyr’s stock value dropped by 83.2% in a single day. The investigation is being led by Hagens Berman, addressing potential violations of securities laws by the company.
Read more →ATYRaTyr Pharma, Inc. (ATYR) Securities Class Action Filed; Class Period Significantly Enlarged -- Hagens Berman
Hagens Berman has filed a new class action complaint against aTyr Pharma, significantly expanding the class period for investors affected by alleged misrepresentation of the drug Efzofitimod. The lawsuit claims that aTyr executives made misleading statements about the drug's effectiveness, which led to inflated stock prices prior to a substantial decline following disappointing trial results. Investors who acquired aTyr securities between November 7, 2024, and September 12, 2025, can now claim losses as the firm investigates the case. The suit coincides with a drastic drop in aTyr's stock, attributed to the failure of the EFZO-FIT study to meet its primary endpoint.
Read more →ATYRATYR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Faruqi & Faruqi, LLP is investigating aTyr Pharma, Inc. for potential securities law violations due to misleading statements concerning its drug, efzofitimod. The firm is encouraging investors, particularly those who suffered losses between January and September 2025, to contact them to discuss legal options. After recent study results showed efzofitimod's ineffectiveness in reducing corticosteroid use, aTyr's stock saw a significant decline. The investigation highlights concerns over the transparency of aTyr's communications with investors.
Read more →ATYR▼ -6.2%on this newsshared move
aTyr Pharma, Inc.’s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman
aTyr Pharma, Inc. is facing a federal class-action lawsuit following an 83% stock price drop after its lead drug, Efzofitimod, failed a Phase 3 trial. The lawsuit alleges that the company made misleading statements regarding the drug's efficacy. Hagens Berman, a leading shareholders rights firm, is investigating whether aTyr misrepresented data and trial outcomes, potentially violating securities laws. The situation escalated after an investor call revealed the trial did not meet its primary endpoint, significantly impacting investor confidence and stock value.
Read more →ATYRaTyr Pharma, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – ATYR
aTyr Pharma, Inc. is currently involved in a class action lawsuit initiated by investors who claim the company engaged in securities fraud. The complaint alleges that aTyr misled investors about the efficacy of its drug, Efzofitimod, particularly regarding its use as a steroid tapering treatment. The issues became apparent following the announcement that the drug did not meet the primary endpoint in a recent study, resulting in a dramatic drop in stock price. Investors still have the option to join the lawsuit by the December 8, 2025 deadline.
Read more →ATYR▲ +7.7%on this newsshared move
ATYR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against aTyr Pharma, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against aTyr Pharma, Inc. regarding misleading statements made during the class period of January 16, 2025, to September 12, 2025. The allegations focus on claims that the company misrepresented the efficacy of its drug, Efzofitimod, particularly in relation to tapering steroid use. Investors affected by these alleged misstatements are encouraged to contact the law firm for potential legal recourse. The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is December 8, 2025.
Read more →ATYR▲ +11.2%on this newsshared move
ATYR Investor Notice: Robbins LLP Reminds Investors of the Securities Fraud Class Action Against aTyr Pharma, Inc.
Robbins LLP has announced a class action lawsuit against aTyr Pharma, Inc. on behalf of investors who acquired its stock from January to September 2025. The lawsuit alleges that aTyr misled shareholders regarding its drug candidate's efficacy in a Phase 3 study, which ultimately failed to meet its primary endpoint. Following these revelations, aTyr's stock price dropped drastically from $6.03 to $1.02 within days. Investors may be eligible to serve as lead plaintiffs in the case to help direct the litigation against the company.
Read more →ATYR▲ +11.2%on this newsshared move
aTyr Pharma, Inc. (ATYR) Securities Class Action Deadline Alert: Shamis & Gentile, P.A. Alerts Investors of Important Lead Plaintiff Deadline of December 8, 2025
aTyr Pharma, Inc. is facing a securities class action lawsuit due to alleged misleading statements about its drug Efzofitimod during a clinical study. The lawsuit was filed for investors who bought stock between January 16, 2025, and September 12, 2025. Following the announcement of disappointing trial results, specifically that EFZO-FIT failed to meet its primary endpoint, aTyr Pharma's stock experienced a significant decline. The firm Shamis & Gentile is alerting impacted investors of a lead plaintiff deadline of December 8, 2025.
Read more →ATYRaTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman
aTyr Pharma, Inc. (NASDAQ: ATYR) experienced a drastic decline in share price, falling over 80% following the announcement that its EFZO-FIT study did not achieve its primary endpoint in treating pulmonary sarcoidosis. This failure has prompted Hagens Berman to launch an investigation into potential misrepresentations regarding the company’s Phase 2 data and the design of its Phase 3 trial. Investors were left disappointed as they had received assurances about the strength of the data and the product's market potential. The aftermath includes significant scrutiny and analyst downgrades, reflecting a severe loss of confidence in the company's prospects.
Read more →ATYR▲ +9.2%on this news· ran to +41% by day 3
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower – Hagens Berman
aTyr Pharma, Inc. experienced a dramatic decline in share price, dropping over 80% on September 15, 2025, following the announcement that its EFZO-FIT trial of efzofitimod for pulmonary sarcoidosis did not meet its primary endpoint. The company's previous assurances regarding the study's promising Phase 2 data now face scrutiny as investors react strongly to the disappointing results. Hagens Berman has launched an investigation into whether aTyr misled investors about the trial's data quality and design, particularly in relation to the claimed market potential.
Read more →ATYR▼ -9.3%on this newsshared move
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025
aTyr Pharma presented additional findings from the Phase 3 EFZO-FIT™ study at the ERS Congress 2025, highlighting significant clinical benefits of efzofitimod in patients with pulmonary sarcoidosis. Improvements were noted in fatigue and general health scores, despite not meeting the primary endpoint. The findings suggest efzofitimod's potential to enhance quality of life and reduce steroid dependence.
Read more →ATYR▼ -9.3%on this newsshared move
EFZO-FIT™: The Largest Ever Interventional Trial in Pulmonary Sarcoidosis
aTyr Pharma is conducting the largest interventional trial for pulmonary sarcoidosis, utilizing efzofitimod. This trial aims to evaluate the efficacy of this innovative treatment in improving patient outcomes. The initiative highlights the company's commitment to addressing unmet medical needs in this area.
Read more →ATYR▲ +5.8%on this newsshared move
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman
aTyr Pharma, Inc. experienced a drastic decline in share price, falling over 80% after its EFZO-FIT study of efzofitimod for pulmonary sarcoidosis failed to meet primary endpoints. The market reaction triggered an investigation by Hagens Berman, a national shareholder rights firm, into potential misrepresentation about the data and trial design. The severe drop in stock price reflects a significant disappointment among investors, as the results contradicted earlier assurances from aTyr regarding the treatment's potential effectiveness and market opportunity.
Read more →ATYRaTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT™ Study Failure Drives Shares 80% Lower -- Hagens Berman
aTyr Pharma, Inc. faces significant scrutiny after the failure of its EFZO-FIT™ study for efzofitimod in treating pulmonary sarcoidosis, leading to an abrupt 80% decline in share prices. The study did not achieve the primary endpoint related to steroid reduction. Hagens Berman, a national shareholders rights firm, has initiated an investigation into whether the company misled investors about the study's data and design. This situation has prompted a widespread sell-off and considerable analyst downgrades.
Read more →ATYR▼ -83.2%on this newsshared move
aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma announced topline results from the Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis. The study did not meet its primary endpoint regarding corticosteroid dose reduction, but showed clinical benefits including improved KSQ-Lung scores and a higher rate of steroid withdrawal in the treatment group. The company plans to engage with the FDA to discuss the future of efzofitimod in this indication.
Read more →ATYR▼ -83.2%on this newsshared move
Forward Looking Statements The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal secur
The Phase 3 EFZO-FIT study of efzofitimod for pulmonary sarcoidosis demonstrated that while there was clinical improvement in the KSQ-Lung score, it did not meet its primary endpoint of change from baseline in mean daily OCS dose at week 48. Approximately 52.6% of patients treated with efzofitimod achieved complete steroid withdrawal compared to 40.2% on placebo. The drug was generally well-tolerated across both dosage groups, confirming its previously observed safety profile. The company plans to engage with the U.S. FDA regarding the path forward for efzofitimod in this indication.
Read more →ATYRaTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update
aTyr Pharma has announced its second quarter 2025 results, highlighting the completion of patient visits in its Phase 3 EFZO-FIT™ study for efzofitimod in pulmonary sarcoidosis. Topline data from this study is anticipated in mid-September, representing a pivotal moment for the company and the sarcoidosis community. Additionally, positive interim data from the Phase 2 EFZO-CONNECT™ study indicates potential benefits for patients with systemic sclerosis-related interstitial lung disease. The firm has also secured over $30 million from an ATM offering, enhancing its financial position to sustain operations through the upcoming data readouts.
Read more →ATYRAshlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update Last patient visit completed in Phase 3
aTyr Pharma has announced the completion of the last patient visit in its pivotal Phase 3 EFZO-FIT study of efzofitimod for pulmonary sarcoidosis, anticipating topline data in mid-September 2025. The company also shared encouraging interim findings from the ongoing Phase 2 EFZO-CONNECT study regarding efzofitimod's efficacy in patients with systemic sclerosis-related interstitial lung disease. Furthermore, aTyr advanced its candidate ATYR0101 for pulmonary fibrosis and noted its recent addition to the Russell 2000 and Russell 3000 Indexes. Financial highlights indicate a stable cash position to support ongoing operations and research activities.
Read more →ATYR▼ -8.2%on this news
aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
aTyr Pharma has announced the completion of the last patient visit in its Phase 3 EFZO-FIT study of efzofitimod for pulmonary sarcoidosis. This marks a significant milestone as it is the largest and first global interventional study for this condition. The company plans to release topline results in the third quarter of 2025, potentially offering new treatment options for patients who currently face limited therapies. Efzofitimod may help to reduce steroid use and enhance the quality of life for patients with this chronic disease.
Read more →ATYRaTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes
aTyr Pharma is set to be included in the Russell 2000 and Russell 3000 Indexes effective June 27, 2025. This inclusion is part of the annual reconstitution of the Russell U.S. Indexes, which track the performance of the largest publicly traded companies in the U.S. The company is recognized for its development of first-in-class medicines targeting fibrosis and inflammation.
Read more →ATYRaTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
aTyr Pharma announced positive interim findings from its Phase 2 EFZO-CONNECT study of efzofitimod in patients with systemic sclerosis-related interstitial lung disease. The analysis showed that 75% of patients experienced clinically significant improvements in skin fibrosis. The study continues to evaluate the efficacy and safety of efzofitimod as it progresses towards the 24-week endpoints.
Read more →ATYRaTyr Pharma to Present at Upcoming Investor Conferences
aTyr Pharma, a clinical stage biotechnology company, announced that CEO Sanjay S. Shukla will present at several investor conferences in May and June 2025. These include the RBC Capital Markets Global Healthcare Conference, the Piper Sandler Virtual Lung Symposium, and the Jefferies Global Healthcare Conference. The company will also hold one-on-one meetings with registered investors and provide webcasts of the events.
Read more →ATYRIncidence, Prevalence, and Mortality of Pulmonary Sarcoidosis with Parenchymal Involvement in the US
The article provides an overview of aTyr Pharma's focus on pulmonary sarcoidosis, particularly its research and clinical trials related to the condition. It highlights the company's scientific approach and pipeline, including the drug Efzofitimod. However, the article lacks specific data on incidence, prevalence, and mortality rates.
Read more →ATYR▲ +5.2%on this news· ran to +16% by day 3shared move
EFZO-FIT™, the Largest Placebo-Controlled Trial in Pulmonary Sarcoidosis
aTyr Pharma is conducting the EFZO-FIT™ trial, the largest placebo-controlled study for pulmonary sarcoidosis. This trial aims to evaluate the efficacy of efzofitimod in patients with this condition. The study's design and scope highlight the company's commitment to addressing unmet medical needs in pulmonary sarcoidosis.
Read more →ATYR▲ +5.2%on this news· ran to +16% by day 3shared move
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
aTyr Pharma showcased three posters on efzofitimod at the ATS 2025 International Conference. The initial findings reveal real-world evidence suggesting a higher burden of pulmonary sarcoidosis, with many patients depending on steroid treatments. The Phase 3 EFZO-FIT study has successfully enrolled a representative patient cohort, highlighting the urgent need for safer therapies. aTyr aims to present topline data in the upcoming third quarter, potentially affirming the drug's role as a transformative treatment for this chronic condition.
Read more →ATYR▲ +5.2%on this news· ran to +16% by day 3shared move
Real-World Treatment Patterns Among Pulmonary Sarcoidosis Patients with Parenchymal Involvement
The article discusses aTyr Pharma's focus on pulmonary sarcoidosis, particularly in patients with parenchymal involvement. It highlights the company's research programs and pipeline, including efzofitimod. The content is primarily informational, detailing the company's structure and offerings without specific news events or updates.
Read more →ATYR▲ +5.2%on this news· ran to +16% by day 3shared move
ATYR0101: A New Approach to Fibrosis
ATYR is focused on developing Efzofitimod, a treatment for fibrosis-related conditions. The company emphasizes its research programs and clinical trials related to pulmonary sarcoidosis and systemic sclerosis-associated interstitial lung disease. The article provides an overview of the company's leadership, governance, and investor relations.
Read more →ATYR▼ -8.5%on this newsshared move
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
aTyr Pharma has advanced its investigational new drug candidate, ATYR0101, to the IND candidate stage for pulmonary fibrosis. The fusion protein, which interacts with LTBP-1 to induce cell death of myofibroblasts, is set to be presented at the 2025 American Thoracic Society Respiratory Innovation Summit. The company anticipates filing an IND application in the second half of 2026, highlighting the therapeutic potential of ATYR0101 in reversing fibrosis.
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update Topline data from Phase
aTyr Pharma has announced its first quarter 2025 results, highlighting their progress on the Phase 3 EFZO-FIT study for efzofitimod in pulmonary sarcoidosis, which is expected to report topline data in Q3 2025. The company has maintained a strong cash position of $78.8 million, anticipated to fund operations for at least another year. Additionally, Dalia R. Rayes has been appointed to lead the global commercial strategy for efzofitimod, marking a significant leadership change as the company aims to enhance its presence in the interstitial lung disease market.
Read more →ATYRaTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update
aTyr Pharma has announced its first quarter 2025 results and a corporate update, highlighting the forthcoming topline data from its Phase 3 EFZO-FIT™ study of efzofitimod in treating pulmonary sarcoidosis, expected in Q3 2025. The company continues to make progress with its clinical programs while also actively enrolling patients in the Phase 2 EFZO-CONNECT™ study for scleroderma-related interstitial lung disease. Notably, Dalia R. Rayes has been appointed as Head of Commercial for the efzofitimod franchise, bringing valuable experience in the biotechnology sector.
Read more →ATYRImmunosuppressive Myeloid Cells Can Be Modulated with NRP2-Targeting Antibody ATYR2810 Leading to Enhanced Anti-Tumor Immunity
The article discusses the potential of the NRP2-targeting antibody ATYR2810 in modulating immunosuppressive myeloid cells, which may enhance anti-tumor immunity. This development could represent a significant advancement in cancer treatment strategies. The focus on myeloid cell modulation highlights a novel approach to improving immune responses against tumors.
Read more →ATYRaTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025
aTyr Pharma announced the presentation of preclinical data for its monoclonal antibody ATYR2810 at the AACR Annual Meeting 2025. The data suggests that ATYR2810 can enhance anti-tumor immunity and increase survival rates in glioblastoma multiforme models. The study indicates that targeting neuropilin-2 may provide a new therapeutic strategy in combination with existing treatments. The research was conducted in collaboration with Stanford Medicine.
Read more →ATYR▲ +5.8%on this news
A Human Histidyl-tRNA Synthetase Splice Variant Therapeutic Targets NRP2 to Resolve Lung Inflammation and Fibrosis
The article discusses a therapeutic approach involving a human histidyl-tRNA synthetase splice variant that targets NRP2. This innovative treatment aims to alleviate lung inflammation and fibrosis, which are critical conditions affecting respiratory health. The findings are set to be published in Science Translational Medicine in 2025, highlighting the potential impact of this research.
Read more →ATYR▲ +8.8%on this news
Dalia R. Rayes
Dalia R. Rayes has been appointed as the Head of Commercial for the Global Efzofitimod Franchise at aTyr since March 2025. With over 20 years of experience in biotech and pharmaceuticals, she has a proven track record in launching rare disease products. Previously, she held significant roles at ChemoCentryx and Actelion, contributing to successful product strategies and launches.
Read more →ATYR▼ -5.7%on this newsshared move
aTyr Pharma to Participate in April Investor Conferences
aTyr Pharma, Inc. has announced its participation in two upcoming investor conferences in April 2025, which include the Jones Healthcare and Technology Innovation Conference in Las Vegas and the Piper Sandler Spring Biopharma Symposium in Boston. The conferences will consist of 1x1 investor meetings, emphasizing aTyr's commitment to engage with potential investors. The company is recognized for its focus on developing therapies using its proprietary tRNA synthetase platform, particularly for conditions like interstitial lung disease.
Read more →ATYR▼ -7.2%on this newsshared move
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
aTyr Pharma has appointed Dalia R. Rayes as the Head of Commercial for its Global Efzofitimod Franchise. With more than 25 years in the biotech sector, she will oversee the commercial strategy for efzofitimod, which is under development for interstitial lung disease. The company is anticipating an important Phase 3 study readout in the upcoming months, underscoring the potential of efzofitimod as a new treatment option for pulmonary sarcoidosis. Ms. Rayes's appointment is seen as crucial for positioning aTyr as a commercial organization in the rare disease market.
Read more →ATYR▲ +12.4%on this news
IMMEDIATE RELEASE Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update Topline
aTyr Pharma announced its fourth quarter and full year 2024 results, highlighting an important year for the company as it completed enrollment in its Phase 3 EFZO-FIT study aimed at evaluating the safety and efficacy of efzofitimod for pulmonary sarcoidosis. The company received a positive data and safety monitoring board review, which recommended that the trial proceed without modifications. Looking ahead, topline data from this pivotal study is anticipated by Q3 2025. Additionally, a publication in Science Translational Medicine supports the mechanism of action of efzofitimod, indicating a promising outlook for its development.
Read more →ATYR▲ +12.4%on this news
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
aTyr Pharma announced its fourth quarter and full year 2024 results, highlighting significant progress in its Phase 3 EFZO-FIT study of efzofitimod for pulmonary sarcoidosis. The enrollment in the study has been completed, and a fourth positive review from the data monitoring board emphasizes the drug's safety profile. The company anticipates topline data in the third quarter of 2025, which could mark a pivotal moment for efzofitimod as a potential treatment option. Additionally, a manuscript detailing efzofitimod's anti-inflammatory effects has been published in Science Translational Medicine.
Read more →ATYR▲ +15.6%on this news· ran to +31% by day 3shared move
aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine
aTyr Pharma, Inc. has announced a peer-reviewed publication in Science Translational Medicine that details the anti-inflammatory mechanism of its lead candidate, efzofitimod. The study highlights efzofitimod's binding to neuropilin-2 (NRP2) and its effects on macrophages, which may help reduce chronic inflammation and fibrosis in interstitial lung disease (ILD). This publication strengthens the rationale for ongoing clinical programs, particularly in pulmonary sarcoidosis and systemic sclerosis-related ILD. Efzofitimod's promising profile has garnered orphan drug and Fast Track designations from regulatory agencies.
Read more →ATYRaTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
aTyr Pharma announced the positive outcome of the fourth interim safety analysis by an independent data and safety monitoring board (DSMB) for efzofitimod in the Phase 3 EFZO-FIT™ study targeting patients with pulmonary sarcoidosis. The DSMB recommended that the study continue without modifications, reinforcing confidence in efzofitimod's safety profile. The study, which includes 268 subjects, evaluates efzofitimod's efficacy and safety as a potential chronic maintenance therapy. Topline results from the trial are expected in the third quarter of this year.
Read more →ATYR▼ -8.2%on this newsshared move
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
aTyr Pharma, a clinical stage biotechnology company, will announce its fourth quarter and full year 2024 financial results on March 13, 2025. The company will host a conference call and webcast to review the results and provide an operational update. aTyr is known for its tRNA synthetase platform, which focuses on developing therapies for fibrosis and inflammation, with its lead candidate being efzofitimod for interstitial lung disease.
Read more →ATYRaTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
aTyr Pharma announced it will present three posters related to its lead candidate, efzofitimod, at the ATS 2025 International Conference. The presentations will cover findings from the ongoing Phase 3 EFZO-FIT study in pulmonary sarcoidosis, which is the largest placebo-controlled trial in this area. Topline data from the study is expected in Q3 2025, further demonstrating the company's commitment to advancing therapies for interstitial lung disease.
Read more →ATYRaTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
aTyr Pharma announced that its CEO, Sanjay S. Shukla, will present at the 43rd Annual J.P. Morgan Healthcare Conference scheduled for January 13-16, 2025, in San Francisco. The presentation will highlight the company’s first-in-class medicines developed from its proprietary tRNA synthetase platform. Subsequently, a one-on-one meeting with registered investors is planned, enhancing engagement opportunities. A webcast of the presentation will also be available for investors on the company's website.
Read more →ATYREric Benevich
Eric Benevich has been a director since December 2024 and serves as the Chief Commercial Officer at Neurocrine Biosciences since May 2015. He oversees commercial development, marketing, and sales for the company's product portfolio. With over 30 years of experience, he has held key positions at major pharmaceutical companies, contributing to the marketing of several well-known drugs.
Read more →ATYRaTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
aTyr Pharma has appointed Eric Benevich to its Board of Directors, effective December 10, 2024. Benevich currently serves as Chief Commercial Officer at Neurocrine Biosciences and has over 30 years of experience in the pharmaceutical industry. His knowledge and expertise in commercial activities are anticipated to be valuable as aTyr Pharma advances its development and commercialization efforts, specifically relating to their lead therapeutic candidate, efzofitimod. The appointment reflects a strategic move to strengthen the company's leadership in preparation for future growth.
Read more →ATYRATYR PHARMA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of aTyr Pharma, Inc., a Delaware corporation (the “Company
aTyr Pharma, Inc. has established a Non-Employee Director Compensation Policy aimed at attracting and retaining high-caliber directors. Non-employee directors will receive an annual retainer of $40,000, with additional compensation based on committee roles. They will also be granted equity options, including a one-time option grant of 100,000 shares and annual grants of 50,000 shares. The grants are designed to vest over time and align the interests of directors with those of shareholders.
Read more →ATYR▼ -6.8%on this newsshared move
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
aTyr Pharma has announced a third positive safety review conducted by an independent DSMB for its Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis. The DSMB has recommended the continuation of the study without modifications, affirming the safety profile of efzofitimod. The study involves 268 patients and focuses on assessing safety and efficacy while providing a potential alternative to traditional corticosteroid treatments. This indication could significantly improve patient outcomes in a field with limited treatment options.
Read more →ATYRAnti-Fibrotic Activity Observed Across Preclinical Models of Pulmonary and Renal Fibrosis for a Potential Therapeutic Based on Asp-tRNA Synthetase
The article discusses the promising anti-fibrotic activity of a potential therapeutic based on Asp-tRNA synthetase, observed across various preclinical models targeting pulmonary and renal fibrosis. The findings suggest significant therapeutic potential, highlighting the importance of this research in addressing fibrotic diseases. The company aTyr is actively advancing its R&D pipeline in this area.
Read more →ATYRA Newly Evolved Domain of Asp-tRNA Synthetase Interacts with Latent Transforming Growth Factor Beta Binding Protein 1 (LTBP-1) to Induce Myofibroblast Apoptosis
The article discusses a newly evolved domain of Asp-tRNA synthetase that interacts with latent transforming growth factor beta binding protein 1 (LTBP-1). This interaction is significant as it induces apoptosis in myofibroblasts. The research highlights potential implications for understanding cellular processes related to fibrosis and other related conditions.
Read more →ATYR▲ +5.1%on this newsshared move
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
aTyr Pharma announced the presentation of preclinical research on ATYR0101's anti-fibrotic effects in lung and kidney fibrosis at the Keystone Symposia. The research demonstrates ATYR0101's mechanism of action by inducing myofibroblast apoptosis through binding with LTBP-1. Promising results indicate significant reductions in fibrosis markers across various preclinical models, suggesting potential as a next-generation therapeutic. The findings will be available on aTyr's website following their presentation on December 9, 2024.
Read more →ATYR▼ -8.9%on this news
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
aTyr Pharma will present two posters detailing its tRNA synthetase candidate ATYR0101 at the upcoming Keystone Symposia on Fibrosis, scheduled for December 8-11, 2024, in Whistler, British Columbia. The presentations will focus on the interaction of Asp-tRNA synthetase with key proteins involved in fibrosis and demonstrate its anti-fibrotic activity in preclinical models. This event highlights aTyr's commitment to delivering innovative therapies targeting fibrosis and inflammation.
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update Enrollment completed in Pha
aTyr Pharma has announced the completion of enrollment in its Phase 3 EFZO-FIT study for efzofitimod in pulmonary sarcoidosis, with topline data expected by Q3 2025. Notably, a recent publication in the European Respiratory Journal showcased positive results regarding corticosteroid relapse rates for efzofitimod. Additionally, the company has highlighted its cash position is sufficient to support operations through the filing of a Biologics License Application. Overall, the company is receiving increased attention for its innovative approaches in treating interstitial lung disease.
Read more →ATYRaTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
aTyr Pharma reported its third quarter 2024 results, announcing the completion of patient enrollment in the Phase 3 EFZO-FIT study on efzofitimod for pulmonary sarcoidosis. The company anticipates topline data from this study in the third quarter of 2025. Additionally, the efficacy of efzofitimod was recognized in a publication in the European Respiratory Journal, highlighting its potential to significantly impact patient treatment. aTyr remains focused on developing innovative therapies aimed at inflammation and fibrosis-related diseases.
Read more →ATYRaTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
aTyr Pharma's lead candidate, efzofitimod, will be showcased at the CHEST 2024 Annual Meeting, highlighting data from a Phase 1b/2a study that demonstrates its effectiveness in pulmonary sarcoidosis. The study suggests efzofitimod can reduce or eliminate steroid use while managing symptoms. The presentation aims to underscore its potential as a new treatment option in a field lacking effective therapies. The company is currently conducting a global Phase 3 study with results expected in the third quarter of 2025.
Read more →ATYRTherapeutic Doses of Efzofitimod Demonstrate Efficacy in Pulmonary Sarcoidosis
The article discusses the efficacy of therapeutic doses of Efzofitimod in treating pulmonary sarcoidosis. The results indicate a significant positive impact on patient outcomes, suggesting that Efzofitimod may be a viable treatment option. This development could enhance the management of pulmonary sarcoidosis and improve patients' quality of life.
Read more →ATYRaTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
aTyr Pharma announced the publication of a post hoc analysis demonstrating the efficacy of its drug efzofitimod in treating pulmonary sarcoidosis, as published in the European Respiratory Journal. The analysis revealed a statistically significant decrease in relapse rates among patients receiving therapeutic doses versus subtherapeutic doses following corticosteroid use. The findings suggest that efzofitimod may offer a promising alternative that minimizes steroid-related side effects, thereby enhancing patient quality of life. The company is currently advancing efzofitimod into Phase 3 trials for further evaluation.
Read more →ATYRaTyr Pharma to Participate in September Investor Conferences
aTyr Pharma, Inc. announced its participation in several upcoming investor conferences in September 2024, including the Wells Fargo Healthcare Conference and the H.C. Wainwright Global Investment Conference. The events will feature corporate presentations and provide opportunities for one-on-one meetings with investors. These conferences aim to boost the company's visibility and strengthen investor relations. Moreover, a webcast of the presentations will be available on the company's website.
Read more →ATYRaTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
aTyr Pharma has completed enrollment in its Phase 3 EFZO-FIT™ study for efzofitimod in patients with pulmonary sarcoidosis, marking a significant milestone. The study, the largest interventional trial in this area, has enrolled 268 patients and aims to report topline data by the third quarter of 2025. Financially, the company ended the second quarter of 2024 with $81.4 million in cash and investments. Additionally, aTyr continues to advance its research into the potential of efzofitimod for other conditions, such as systemic sclerosis-related interstitial lung disease.
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update Phase 3 EFZO-FIT study of
aTyr Pharma announced its second quarter 2024 results and an update on its clinical programs. The company completed enrollment for its Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis, expecting topline data in the third quarter of 2025. They also continue to enroll patients in the Phase 2 EFZO-CONNECT study for systemic sclerosis-related ILD. aTyr reported a robust cash position, ending the quarter with $81.4 million.
Read more →ATYRaTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
aTyr Pharma announced the appointment of Dr. Jayant Aphale as Vice President of Technical Operations, enhancing its executive leadership team. Dr. Aphale brings over 30 years of experience in the pharmaceutical industry, having held senior roles in process development and manufacturing. His expertise will support aTyr's upcoming pivotal Phase 3 data release for their lead product, efzofitimod, which is aimed at treating pulmonary sarcoidosis. The company is preparing for a potential Biologics License Application in the near future.
Read more →ATYR▼ -6.6%on this news
aTyr Pharma Announces Research Study with Stanford Medicine
aTyr Pharma has announced a research study collaboration with Stanford Medicine to investigate the effects of novel NRP2-targeted antibodies in treating glioblastoma multiforme (GBM). Led by Dr. Michael Lim, the study focuses on reversing immunosuppression in GBM through combination therapies that may involve anti-PD-1 and other agents. aTyr's leadership expresses optimism about the potential of NRP2 in understanding immune responses in this aggressive cancer, emphasizing the need for new treatment strategies.
Read more →ATYR▲ +13.4%on this news· ran to +36% by day 3
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma has successfully completed enrollment in its global pivotal Phase 3 EFZO-FIT™ study for efzofitimod, involving 268 patients across 85 centers in nine countries. This study is noted as the largest interventional trial for pulmonary sarcoidosis, addressing a significant unmet need for therapeutic options. Results are anticipated in Q3 2025 and may provide critical insights for future sarcoidosis research and treatment developments.
Read more →ATYRaTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
aTyr Pharma, Inc. announced a change in its Nasdaq ticker symbol from 'LIFE' to 'ATYR,' effective June 5, 2024. This rebranding aims to better reflect the company's focus as it advances its lead therapeutic candidate, efzofitimod, through a pivotal Phase 3 study for pulmonary sarcoidosis. The company emphasizes that this new symbol will enhance its visibility among stakeholders. No action is required from existing stockholders, as the common stock will continue to be traded on the Nasdaq Capital Market without any changes in CUSIP.
Read more →ATYREfzofitimod is an Immunomodulator of Myeloid Cell Function and Novel Therapeutic Candidate for Interstitial Lung Diseases
aTyr Pharma is advancing its investigational drug Efzofitimod, which acts as an immunomodulator targeting myeloid cell function. This novel therapeutic candidate is being developed for interstitial lung diseases, including pulmonary sarcoidosis and systemic sclerosis-associated interstitial lung disease (SSc-ILD). The company emphasizes its commitment to research and clinical trials to support the drug's efficacy and safety.
Read more →ATYRaTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
aTyr Pharma announced that it will present findings on its lead candidate, efzofitimod, at the ATS 2024 International Conference. The data demonstrates efzofitimod's unique mechanism of action in modulating myeloid cells, which may lead to anti-inflammatory benefits in patients with pulmonary sarcoidosis, a significant form of interstitial lung disease. The anticipated presentation aims to convey confidence in efzofitimod's potential as a treatment for ILD, currently being explored in pivotal Phase 3 studies.
Read more →ATYRaTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
aTyr Pharma has received a second positive recommendation from the independent data and safety monitoring board (DSMB) for its ongoing Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis. The DSMB's review supports the favorable safety profile of efzofitimod, which aims to offer a safer, non-steroidal treatment option compared to standard corticosteroid therapies that can cause significant side effects. The study is designed to evaluate the efficacy and safety of efzofitimod over 52 weeks in a randomized, double-blind approach, involving patients from multiple countries.
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update Phase 3 EFZO-FIT study of e
aTyr Pharma announced its first quarter 2024 results and provided an update on its clinical studies for efzofitimod, a treatment for interstitial lung disease. The company is progressing with its Phase 3 EFZO-FIT study for pulmonary sarcoidosis, expecting to complete enrollment in the second quarter of 2024. Additionally, aTyr reported a solid cash position, sufficient to support its operational needs through the anticipated filing of a Biologics License Application. The company is also actively enrolling participants in the Phase 2 EFZO-CONNECT study for systemic sclerosis-related interstitial lung disease.
Read more →ATYRaTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
aTyr Pharma reported its first quarter 2024 results, highlighting progress in its clinical studies for efzofitimod, aimed at treating interstitial lung diseases. The Phase 3 EFZO-FIT study is nearing enrollment completion, with expectations to finish in Q2 2024. The company maintains a strong cash position of $87.7 million, which supports ongoing operations and development activities. Additionally, aTyr continues its Phase 2 study for SSc-ILD and plans to present findings at the upcoming ATS 2024 International Conference.
Read more →ATYRAlanyl-tRNA synthetase fragment binds to FGFR4 and induces morphological changes and downstream signaling in liver cells with functional similarities to FGF2
The article discusses the binding of an alanyl-tRNA synthetase fragment to FGFR4, which leads to morphological changes and downstream signaling in liver cells. This mechanism exhibits functional similarities to FGF2, suggesting potential therapeutic applications. The findings underscore the significance of extracellular tRNA synthetase biology in liver cell function.
Read more →ATYRaTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
aTyr Pharma announced its fourth quarter and full year 2023 results, highlighting meaningful progress in its clinical development programs, particularly for efzofitimod, intended for treating interstitial lung disease. The Phase 3 EFZO-FIT study is expected to complete enrollment by the second quarter of 2024, and an Individual Patient Expanded Access Program has been launched for patients completing this study. With a solid cash position of $101.7 million, the company believes it can sustain operations through the anticipated filing of a Biologics License Application for efzofitimod.
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update Phase 3 EFZO
aTyr Pharma has announced its fourth quarter and full year 2023 results, highlighting significant progress in its clinical development programs for efzofitimod, particularly in pulmonary sarcoidosis and systemic sclerosis-related interstitial lung disease. The company reported a solid financial position with $101.7 million in cash, sufficient to support operations through a planned Biologics License Application filing. Additionally, they are set to complete enrollment in the Phase 3 EFZO-FIT study by the second quarter of 2024, while also launching an expanded access program for patients.
Read more →ATYRaTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
aTyr Pharma, Inc. has announced it will report its fourth quarter and full year 2023 financial results on March 14, 2024, after market close. The company will host a conference call and webcast to review these results and provide an operational update. This call emphasizes a commitment to stakeholder communication and transparency in its ongoing clinical developments.
Read more →ATYRaTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
aTyr Pharma has announced an Individual Patient Expanded Access Program (EAP) for its lead candidate, efzofitimod, for patients who complete the Phase 3 EFZO-FIT study for pulmonary sarcoidosis. This initiative is based on feedback from investigators and patients, aiming to provide continued access to the investigational therapy outside the clinical trial setting. The EAP underscores aTyr's commitment to the sarcoidosis community, particularly for a condition with significant unmet needs in treatment options.
Read more →ATYREfzofitimod Promotes Macrophages with Anti-inflammatory Profile via Neuropilin-2 Receptor
The article discusses aTyr Pharma's efzofitimod, which promotes macrophages with an anti-inflammatory profile via the neuropilin-2 receptor. It highlights the company's focus on research programs and clinical trials related to pulmonary sarcoidosis and systemic sclerosis-associated interstitial lung disease. However, no specific developments or results are detailed in the text.
Read more →ATYRDemonstration of an Isoform-Specific Anti-inflammatory Role for Neuropilin-2 Through a Novel Interaction with the Chemokine Ligand 21
The article discusses aTyr Pharma's demonstration of the anti-inflammatory role of Neuropilin-2 through its interaction with Chemokine Ligand 21. This research highlights the potential therapeutic implications for conditions like pulmonary sarcoidosis and SSc-ILD. The findings contribute to the understanding of the molecular mechanisms involved in inflammation.
Read more →ATYRaTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
aTyr Pharma announced it will present two posters at the Keystone Symposia, showcasing research on the neuropilin-2 receptor's role in immune regulation. The findings suggest efzofitimod, the company's lead therapy, may provide significant anti-inflammatory effects and could be a breakthrough treatment for pulmonary sarcoidosis and other interstitial lung diseases. This research validates the therapeutic potential of modulating myeloid cells through neuropilin-2 and highlights the need for more effective treatments in this area.
Read more →ATYRaTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
aTyr Pharma announced the appointment of Dr. Wayne A. I. Frederick as an advisor. Dr. Frederick, the former President of Howard University, brings extensive experience in addressing healthcare disparities, particularly in interstitial lung diseases like pulmonary sarcoidosis. His involvement is expected to enhance aTyr's efforts in developing efzofitimod, a treatment aimed at underserved communities disproportionately affected by these conditions.
Read more →ATYRAndrea Wilson
Andrea Wilson, a prominent advocate for sarcoidosis patients, co-founded the Foundation for Sarcoidosis Research in 2000 after her own diagnosis. With over 20 years of leadership, including serving as President and Chairwoman, she has significantly contributed to raising awareness and funding for research. In recognition of her efforts, she was awarded the World Sarcoidosis Person of the Year in 2014.
Read more →ATYRWayne A.I. Frederick, M.D.
Wayne A.I. Frederick, M.D., recently concluded his tenure as President of Howard University, where he served from 2014 to 2023. He is a prominent cancer surgeon and professor, recognized for his research on healthcare disparities. Dr. Frederick holds multiple degrees and has held various leadership roles in academia and healthcare organizations.
Read more →ATYREfzofitimod, a First-in-Class NRP2-Targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models
Efzofitimod, developed by aTyr Pharma, is a first-in-class immunomodulator targeting NRP2. It has shown effectiveness in preclinical models for treating rheumatoid arthritis and associated lung fibrosis. This innovative approach may provide new therapeutic options for patients suffering from these conditions.
Read more →ATYRaTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
aTyr Pharma presented a poster at the ACR Convergence 2023 detailing the preclinical effects of efzofitimod in rheumatoid arthritis and its associated lung disease. The data suggests that efzofitimod can significantly ameliorate disease severity and inflammation in preclinical models. This first-in-class immunomodulator could hold promise for treating a range of immune-mediated diseases, although it is currently focused on interstitial lung disease applications. The company highlighted the need for safer and effective treatments for these conditions amidst a landscape of limited therapeutic options.
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update Phase 3 EFZO-FIT study of e
aTyr Pharma has announced its third quarter 2023 financial results and an update on its clinical programs. The company is progressing its Phase 3 EFZO-FIT study for efzofitimod in pulmonary sarcoidosis and has initiated patient dosing in the Phase 2 EFZO-CONNECT study for SSc-ILD. Notably, the Phase 3 study received a positive review from the data safety monitoring board. The company ended the quarter with $105.6 million in cash, which is expected to support its operations through the Biologics License Application filing for efzofitimod.
Read more →ATYRaTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
aTyr Pharma reported its third-quarter 2023 results, highlighting significant progress with its lead therapeutic candidate, efzofitimod. The company is advancing its Phase 3 EFZO-FIT study in pulmonary sarcoidosis, expecting to complete enrollment by early Q2 2024. Additionally, patient dosing has begun in the Phase 2 EFZO-CONNECT study for systemic sclerosis-related interstitial lung disease. Financially, aTyr ended the quarter with $105.6 million, sufficing to support operations through crucial upcoming milestones.
Read more →ATYRExposure-Response Analyses of Efzofitimod in Patients With Pulmonary Sarcoidosis
The article discusses aTyr Pharma's focus on efzofitimod, a treatment for pulmonary sarcoidosis. It highlights the company's research programs and clinical trials related to this condition. However, specific results or findings from the exposure-response analyses are not detailed in the text provided.
Read more →ATYRaTyr Pharma to Present at November Investor Conferences
aTyr Pharma, a clinical stage biotechnology company, announced that its CEO, Dr. Sanjay S. Shukla, will present at two upcoming investor conferences in November 2023. The conferences include the Jefferies London Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference. During these events, aTyr's management will also hold one-on-one meetings with registered investors to discuss the company's tRNA synthetase platform and lead therapeutic candidate, efzofitimod, aimed at treating interstitial lung disease.
Read more →ATYRaTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD
aTyr Pharma announced that it has dosed the first patient in its Phase 2 EFZO-CONNECT™ study, evaluating efzofitimod for systemic sclerosis-related interstitial lung disease (SSc-ILD). The study aims to determine the efficacy, safety, and tolerability of efzofitimod compared to placebo over a 28-week period. This study follows favorable preclinical results and reflects the urgent need for effective treatments in a patient population with limited options. Efzofitimod is positioned to target underlying disease mechanisms without causing immune suppression.
Read more →ATYRaTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
aTyr Pharma presented findings from a post-hoc analysis of a Phase 1b/2a study of efzofitimod for pulmonary sarcoidosis at the ERS International Congress 2023. The data showed that patients receiving 3.0 and 5.0 mg/kg of efzofitimod had a significantly lower relapse rate of 7.7% following steroid taper compared to 54.4% in the placebo group. Additionally, there were significant improvements in forced vital capacity (FVC) and patient-reported outcomes. The company is currently conducting a Phase 3 study to further evaluate efzofitimod's efficacy and safety in this patient population.
Read more →ATYRTherapeutic Doses of Efzofitimod Significantly Improve Multiple Pulmonary Sarcoidosis Efficacy Measures
Atyr Pharma has reported that therapeutic doses of efzofitimod significantly improve multiple efficacy measures in patients with pulmonary sarcoidosis. The results from clinical trials indicate a promising therapeutic profile for efzofitimod. This development highlights the potential of the drug in addressing this challenging condition.
Read more →ATYREfzofitimod: A Novel Therapeutic Candidate for SSc-ILD
The article discusses aTyr Pharma's therapeutic candidate Efzofitimod, which is being researched for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD). The company highlights its R&D pipeline and the scientific basis of Efzofitimod, focusing on its potential applications in clinical trials. Further details on the company's governance and investor relations are also provided.
Read more →ATYRLisa Carey
Lisa Carey has been appointed Vice President of Clinical Operations at aTyr since May 2023. With over 30 years of experience, she previously served as Sr. Director of Clinical Operations, managing clinical programs like efzofitimod. Carey's career includes roles at Vertex Pharmaceuticals and Genetics Institute, showcasing her expertise in clinical trials and operations.
Read more →ATYRaTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
aTyr Pharma announced that its CFO, Jill Broadfoot, will deliver a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023, in New York. The company specializes in developing first-in-class biotherapeutics, particularly focusing on the tRNA synthetase platform. Alongside the presentation, management will engage with investors during scheduled one-on-one meetings. A webcast of the event will be available on the company’s website, with a replay accessible for 90 days post-event.
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update Phase 3 EFZO-FIT study of
aTyr Pharma has announced its second quarter 2023 results, highlighting the ongoing progress of its Phase 3 EFZO-FIT study for efzofitimod in pulmonary sarcoidosis. The company also plans to initiate a Phase 2 EFZO-CONNECT study for patients with systemic sclerosis-associated ILD in the third quarter. With a strong cash position of $112 million, aTyr is well-positioned to support its clinical programs and has received orphan drug designation from the European Commission for efzofitimod. Additionally, the company will present new data at the European Respiratory Society International Congress in September 2023.
Read more →ATYRaTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update
aTyr Pharma reported its second quarter results for 2023, highlighting ongoing clinical development for its lead candidate efzofitimod in pulmonary sarcoidosis. The company is currently enrolling patients in a pivotal Phase 3 trial and plans to initiate a Phase 2 trial for systemic sclerosis-associated interstitial lung disease. aTyr also received orphan drug designation for efzofitimod in the EU, which may offer benefits such as marketing exclusivity. The firm ended the quarter with $112 million in cash, supporting its operations and development activities well into 2026.
Read more →ATYRaTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference
aTyr Pharma announced the presentation of its lead therapeutic candidate, efzofitimod, at the WASOG Conference in Stockholm. This drug is currently in a Phase 3 study targeting pulmonary sarcoidosis, with the potential to become a groundbreaking treatment using a unique myeloid-cell focused mechanism. The ongoing study is expected to enroll patients globally and may provide significant advancements in treating this debilitating disease. Clinical data supporting efzofitimod indicates safety and potential benefits compared to existing therapies.
Read more →ATYRaTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023)
aTyr Pharma is set to present its research advancements at the 13th International Symposium of Aminoacyl-tRNA Synthetases in Ontario, Canada. The company will highlight its progress with efzofitimod, which has shown promise as a treatment for interstitial lung disease. Additionally, new findings suggest a connection between certain genetic conditions and reduced levels of tRNA synthetase HARS, providing insights into respiratory diseases. aTyr continues to develop therapeutics based on its proprietary tRNA synthetase platform.
Read more →ATYRaTyr Pharma to Present at the 2023 Jefferies Healthcare Conference
aTyr Pharma, Inc. announced that its CEO, Dr. Sanjay S. Shukla, will present a corporate overview at the 2023 Jefferies Healthcare Conference in New York. The event will take place from June 7 to 9, with the presentation scheduled for June 8. Attendees will have the opportunity for one-on-one meetings with company management. The presentation will discuss the company's proprietary tRNA synthetase platform and its lead clinical-stage product candidate, efzofitimod, aimed at treating fibrotic lung disease.
Read more →ATYRaTyr Pharma Presents New Data on Efzofitimod Mechanism of Action and Positive Exposure-Response at the American Thoracic Society 2023 International Conference
aTyr Pharma presented new data at the American Thoracic Society 2023 International Conference, highlighting the mechanism of action of efzofitimod. The research shows its potential as a transformative therapy for pulmonary sarcoidosis through modulation of myeloid cells. Phase 1b/2a study results demonstrate positive exposure-response for multiple clinically relevant endpoints, supporting efzofitimod's efficacy. The company's efforts focus on developing efzofitimod as a novel treatment option to address chronic inflammation in interstitial lung disease.
Read more →ATYRaTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference
aTyr Pharma, Inc. will present at the 2023 RBC Capital Markets Global Healthcare Conference in New York on May 16, 2023. The presentation will include a fireside chat format led by Dr. Sanjay S. Shukla, the company's CEO. Investors attending the conference will have the opportunity to engage in one-on-one meetings with company management. aTyr's focus on its tRNA synthetase platform and drugs like efzofitimod marks a significant aspect of its developmental strategy.
Read more →ATYRaTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update
aTyr Pharma announced its first quarter 2023 results, highlighting progress in its clinical program for efzofitimod, specifically for pulmonary sarcoidosis and systemic sclerosis-associated interstitial lung disease. The company reported a strong cash position of $117.6 million at the end of the quarter, enhancing its capabilities to fund ongoing trials. Additionally, aTyr plans to present multiple findings related to efzofitimod at the upcoming American Thoracic Society 2023 Conference, further establishing its position in the field of fibrotic lung diseases.
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update Phase 3 EFZO-FIT
aTyr Pharma has announced its first quarter 2023 results, highlighting ongoing enrollment in their Phase 3 EFZO-FIT study for efzofitimod in patients with pulmonary sarcoidosis. The company plans to initiate a Phase 2 proof-of-concept study for efzofitimod in systemic sclerosis-associated interstitial lung disease in Q3 2023. Financially, aTyr remains strong with $117.6 million in cash, which is expected to run through 2026. Multiple presentations for efzofitimod are planned at the upcoming American Thoracic Society 2023 International Conference.
Read more →ATYRaTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting
aTyr Pharma presented key preclinical research findings on ATYR2810 at the 2023 AACR Annual Meeting. The study demonstrated that ATYR2810, a monoclonal antibody, effectively inhibits tumor growth and enhances response to chemotherapy in aggressive cancer models. Notably, the research highlighted the potential of blocking the NRP2/VEGF-C signaling axis to improve therapeutic outcomes in cancers associated with high VEGF-C levels. This innovative approach could offer new hope for overcoming therapy resistance in challenging cancer types.
Read more →ATYRaTyr Pharma Announces First Major Review Article for Efzofitimod Published in the Journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases
aTyr Pharma has announced the publication of a major review article on efzofitimod, a novel anti-inflammatory agent for sarcoidosis, in a peer-reviewed journal. This article, authored by leading researchers, details efzofitimod's mechanism of action and its potential benefits in reducing corticosteroid use while improving lung function and quality of life. Currently undergoing a pivotal Phase 3 clinical trial, efzofitimod is positioned as a transformative therapy for patients suffering from pulmonary sarcoidosis. The publication marks a significant step in consolidating the clinical understanding of this innovative treatment.
Read more →ATYRaTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution
aTyr Pharma announced the presentation of findings identifying LTBP1 as a binding partner for their tRNA synthetase candidate, ATYR0101, at the Keystone Symposia on Fibrosis. The data suggests that ATYR0101 may have therapeutic potential in treating fibrotic pathologies. The oral presentation is scheduled for March 21, 2023, and details of the findings will be shared, emphasizing the role of LTBP1 in the fibrotic process and the evolution of tRNA synthetase functionalities.
Read more →ATYRaTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies
aTyr Pharma and the Foundation for Sarcoidosis Research are hosting a Virtual Town Hall on March 25, 2023, to discuss sarcoidosis treatment options. The panel will feature several experts, including aTyr's President, who will highlight the limitations of steroid treatments and the potential of new investigational therapies. Efzofitimod, currently under clinical development for pulmonary sarcoidosis, aims to improve therapeutic outcomes for patients. The event aims to educate patients about transitioning from steroids to alternative therapies and is part of the lead-up to Sarcoidosis Awareness Month in April.
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update Ph
aTyr Pharma has announced its fourth quarter and full year 2022 results, highlighting the advancement of its lead therapeutic candidate efzofitimod. The drug is currently undergoing a pivotal Phase 3 study for pulmonary sarcoidosis, the largest of its kind. Additionally, a Phase 2 proof-of-concept study for systemic sclerosis-associated ILD is anticipated to start in 2023. The company successfully raised funds through a public offering, providing sufficient cash to support these clinical trials and operations through 2026.
Read more →ATYRaTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
aTyr Pharma reported its fourth quarter and full year 2022 financial results and provided a corporate update. The company is advancing its lead candidate, efzofitimod, into a pivotal Phase 3 study for pulmonary sarcoidosis, with enrollment ongoing in the U.S., Europe, and Japan. Additionally, a Phase 2 proof-of-concept study for efzofitimod in systemic sclerosis-associated interstitial lung disease is anticipated to start in 2023. A recent common stock offering was successful in raising $52 million, which supports their clinical development plans through 2026.
Read more →ATYRaTyr Pharma to Present at March Investor Conferences
aTyr Pharma, Inc., a biotherapeutics company, announced its participation in two upcoming investor conferences in March 2023. The presentations will include a fireside chat at the 35th Annual Roth Conference and a corporate presentation at the Oppenheimer 33rd Annual Healthcare Conference. In addition to these sessions, company management will meet one-on-one with registered investors. aTyr is focused on developing medicines from its proprietary tRNA synthetase platform, with a highlight on its clinical-stage product candidate, efzofitimod.
Read more →ATYRaTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results
aTyr Pharma has announced it will report its fourth quarter and full year 2022 financial results on March 9, 2023. The company will host a conference call and webcast to discuss these results and provide an operational update. aTyr is focused on developing first-in-class biotherapeutics using its proprietary tRNA synthetase biology platform, particularly aiming at fibrotic lung diseases.
Read more →ATYRaTyr Pharma Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND Application
aTyr Pharma announced the initiation of a Phase 2 study for efzofitimod targeting systemic sclerosis-associated interstitial lung disease (SSc-ILD), following FDA approval of an IND application. The study aims to evaluate the drug's efficacy, safety, and tolerability through a randomized, double-blind, placebo-controlled design over 28 weeks. Efzofitimod has demonstrated positive results in preclinical models, offering hope for a new treatment for SSc-ILD, a condition with limited existing therapies.
Read more →ATYRaTyr Pharma Announces Pricing of Public Offering of Common Stock
aTyr Pharma has announced the pricing of a public offering of 22,225,000 shares at $2.25 per share, aiming to raise about $50 million. The funds will primarily support general corporate purposes, including the development of efzofitimod and a planned Phase 2 study for systemic sclerosis-associated interstitial lung disease. The offering, underwritten by RBC Capital Markets and H.C. Wainwright & Co., is expected to close on or about February 13, 2023, pending customary conditions.
Read more →ATYRaTyr Pharma Announces Commencement of Public Offering of Common Stock
aTyr Pharma, Inc. has announced the commencement of an underwritten public offering of its common stock, which will include an option for underwriters to purchase additional shares. The funds raised will primarily support general corporate activities, particularly the ongoing development of efzofitimod, including a planned Phase 2 study for patients with systemic sclerosis-associated interstitial lung disease. The offering is subject to market conditions, and its completion is uncertain.
Read more →ATYRaTyr Pharma Announces Achievement of Development Milestone by Partner Kyorin Pharmaceutical, Co., Ltd.
aTyr Pharma announced that its partner, Kyorin Pharmaceutical, has dosed the first patient in Japan for the EFZO-FIT™ Phase 3 study evaluating efzofitimod for pulmonary sarcoidosis. This milestone has triggered a $10 million payment to aTyr as part of their collaboration agreement. The study aims to assess the efficacy and safety of efzofitimod, an immunomodulatory therapy, in a global setting with several centers in the U.S. and Japan now open for enrollment. Efzofitimod has received significant designations from regulatory agencies, signifying its potential importance in treating pulmonary sarcoidosis.
Read more →ATYRaTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 2023 International Conference
aTyr Pharma announced plans to present new data regarding efzofitimod's mechanism of action and exposure-efficacy analysis at the ATS 2023 International Conference. These presentations aim to share significant findings that underscore the potential of efzofitimod in treating pulmonary sarcoidosis. CEO Sanjay S. Shukla emphasized the drug's ability to modulate myeloid cells and its demonstrated clinical benefits in prior studies. Current development includes a pivotal Phase 3 study focusing on this drug's efficacy.
Read more →ATYRaTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis
aTyr Pharma has been granted a patent by the European Patent Office for its lead candidate, efzofitimod, in combination with pirfenidone for treating lung inflammation and fibrosis. This patent is significant as efzofitimod is currently under clinical development for pulmonary sarcoidosis and could potentially benefit other interstitial lung diseases. The patent builds upon encouraging preclinical data indicating efzofitimod's effectiveness in models of idiopathic pulmonary fibrosis. The patent allows for further advancement in aTyr's diverse pipeline of therapeutics targeting related conditions.
Read more →ATYRaTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment
LTBP1 is key regulator of TGF-β, a major driver of fibrosis. Latest target identified from company’s platform in collaboration with Dualsystems Biotech AG. SAN DIEGO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the di
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update First patient dos
IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update First patient dosed in Phase 3 EFZO-FIT study in patients with pulmona
Read more →ATYRaTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update
First patient dosed in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis; multiple centers in the U.S. are open for enrollment. Company to prioritize resources towards largest value driver efzofitimod program. Ended the third quarter 2022 with $79.6 million in cash
Read more →ATYRaTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST
First therapy in sarcoidosis to reduce steroid burden while demonstrating improvements in key physiologic and quality of life measures. Global pivotal Phase 3 EFZO-FIT™ study currently enrolling. SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a b
Read more →ATYRaTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report third quarter 2
Read more →ATYRaTyr Pharma to Present at the Jefferies London Healthcare Conference
SAN DIEGO, Oct. 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., Presiden
Read more →ATYRaTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets
SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has entered
Read more →ATYRaTyr Pharma to Participate in RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium
SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., Presiden
Read more →ATYRaTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies
SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the U.S. Patent and Trademark Office
Read more →ATYRaTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
Multiple centers in the U.S. are open for enrollment for double-blind, randomized, placebo-controlled study. Primary endpoint will evaluate steroid-sparing effect of efzofitimod compared to placebo. EFZO-FIT™ builds on positive results from Phase 1b/2a study which demonstrated
Read more →ATYRaTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Second Fast Track designation for efzofitimod clinical program. Efzofitimod previously received FDA orphan drug designation for systemic sclerosis (SSc). SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company eng
Read more →ATYRaTyr Pharma to Present at the Life Sciences Investor Forum on September 15th
SAN DIEGO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Ashlee Dunston, Direc
Read more →ATYRaTyr Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022
SAN DIEGO , Sept. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., Presid
Read more →ATYRaTyr Pharma to Present Poster at the European Respiratory Society (ERS) International Congress 2022
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present a poster on
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update First sites init
IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update First sites initiated in Phase 3 EFZO-FIT study in patients with pulm
Read more →ATYRaTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update
First sites initiated in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis. FDA granted Fast Track designation for efzofitimod for the treatment of pulmonary sarcoidosis. Ended the second quarter 2022 with $89.3 million in cash, restricted cash, cash equivalents an
Read more →ATYRaTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis
SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that
Read more →ATYRaTyr Pharma to Webcast Conference Call Reporting Second Quarter 2022 Financial Results
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report second quarter
Read more →ATYRaTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment
Poster to be presented at the Keystone Symposia on Tissue Fibrosis and Repair. Second tRNA synthetase receptor identified from company’s platform. Findings suggest AARS fragment may have therapeutic potential in fibrosis, inflammation and cancer. SAN DIEGO, June 14, 2022 (GLOB
Read more →ATYRaTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference
SAN DIEGO, June 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that Leslie A. Nangle, Ph.D., Vice
Read more →ATYRaTyr Pharma to Present at the 2022 Jefferies Healthcare Conference
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines from its proprietary tRNA synthetase biology platform, today announced that Sanjay S. Shukla, M.D., M.S., Pres
Read more →ATYRaTyr Pharma Presents Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate dose-dependent improvements in key physiologic and quality of life measures in context of a steroid taper. Efzofitimod treatment reduces pro-inflammatory serum biomarkers in pulmonary sar
Read more →ATYRaTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis
Global pivotal EFZO-FIT™ study expected to begin in the third quarter of 2022 Primary endpoint will evaluate steroid sparing effect of efzofitimod compared to placebo SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged
Read more →ATYRaTyr Pharma to Present at Upcoming Investor Conferences in May
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRNA synthetase biology platform, today announced that the company will present at two
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update Company to presen
IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update Company to present clinical data for efzofitimod (ATYR1923) in pulmona
Read more →ATYRaTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update
Company to present clinical data for efzofitimod (ATYR1923) in pulmonary sarcoidosis at upcoming American Thoracic Society International Conference in May. Planned registrational study of efzofitimod in pulmonary sarcoidosis on track to initiate in the third quarter of 2022. FD
Read more →ATYRaTyr Pharma to Webcast Conference Call Reporting First Quarter 2022 Financial Results
SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report first quarter 2022 financial results an
Read more →ATYRaTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic Sclerosis
SAN DIEGO, April 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Food and Drug Administration
Read more →ATYRaTyr Pharma Presents Preclinical Research Characterizing Effects of ATYR2810 in Highly Aggressive Tumor Subtypes at the 2022 AACR Annual Meeting
SAN DIEGO, April 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced a poster presentation at the 2022 American Association fo
Read more →ATYRaTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate safety and dose dependent trends of improvement compared to placebo for key efficacy endpoints. Efzofitimod treatment reduces pro-inflammatory serum biomarkers in pulmonary sarcoidosis pa
Read more →ATYRaTyr Pharma Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update
FDA End-of-Phase 2 meeting provides development pathway for efzofitimod (ATYR1923) in pulmonary sarcoidosis; planned registrational study to initiate in the third quarter of 2022. Company ended 2021 with $107.9 million in cash, cash equivalents and investments. Company to host
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update FD
IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update FDA End-of-Phase 2 meeting provides development pathway
Read more →ATYRaTyr Pharma Announces Positive End-of-Phase 2 Meeting with FDA on Efzofitimod for the Treatment of Pulmonary Sarcoidosis
SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the positive outcome of a Type B
Read more →ATYRaTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present a poster at the upcoming Am
Read more →ATYRaTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2021 Financial Results
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report fourth quarter and full year 2021 fin
Read more →ATYRaTyr Pharma to Present at Upcoming Investor Conferences in March
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Ex
Read more →ATYRaTyr Pharma to Participate in Panel at National Institutes of Health Rare Disease Day
SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Exe
Read more →ATYRaTyr Pharma to Present at BIO CEO & Investor Conference
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Exe
Read more →ATYRaTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name
SAN DIEGO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the United States Adopted Names (USAN) Council and th
Read more →ATYRaTyr Pharma Announces FDA Orphan Drug Designation for ATYR1923 for Treatment of Sarcoidosis
SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Food and Drug Administration
Read more →ATYRaTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Jill Broadfoot, Chief Financial Officer, will present
Read more →ATYRaTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources
SAN DIEGO, Dec. 24, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Danielle Campbell to Vice President, Hu
Read more →ATYRaTyr Pharma to Present at Antibody Engineering & Therapeutics Conference
SAN DIEGO, Dec. 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced a presentation at the Antibody Engineering & Therapeutics
Read more →ATYRaTyr Pharma and FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement for aTyr’s Lead Therapeutic Candidate ATYR1923
SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and FUJIFILM Diosynth Biotechnologies, a leading contract development and
Read more →ATYRaTyr Pharma to Present at Upcoming Investor Conferences in November
SAN DIEGO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Exe
Read more →ATYRaTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update
Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof-of-concept for ATYR1923 and validation for tRNA synthetase biology platform and NRP2 target. Registrational trial for ATYR1923 in pulmonary sarcoidosis expected to initi
Read more →ATYRaTyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, ATYR2810, on Tumor Associated Macrophages at the Society for Immunotherapy of Cancer Annual Meeting
Findings provide key insights into ATYR2810’s potential mechanism of action, including ability to modulate key immune cells involved in tumor progression, metastasis and therapy resistance. Data will support the clinical development of ATYR2810, including a Phase 1 study in canc
Read more →ATYRaTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial Results
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report third quarter 2021 financial results a
Read more →ATYRaTyr Pharma to Participate in Piper Sandler Investor Lung Day
SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Exe
Read more →ATYRaTyr Pharma Announces Appointment of Robert W. Ashworth, PhD, as Vice President of Regulatory Affairs
SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Robert W. Ashworth, Ph.D., to Vice Pres
Read more →ATYRaTyr Pharma Announces Poster Presentation at the Society for Immunotherapy of Cancer Annual Meeting
SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present a poster at the upcoming Soc
Read more →ATYRaTyr Pharma Announces Closing of $86.3 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, Sept. 20, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the closing of an underwritten public offe
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces Pricing of $75 million Public Offering of Common Stock
IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces Pricing of $75 million Public Offering of Common Stock SAN DIEGO - September 16, 2021 - aTyr Pharma, Inc. (Nasdaq: LIFE), a cli
Read more →ATYRaTyr Pharma Announces Pricing of $75 Million Public Offering of Common Stock
SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the pricing of an underwritten public offe
Read more →ATYRaTyr Pharma to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Ex
Read more →ATYRaTyr Pharma Announces Proposed Public Offering of Common Stock
SAN DIEGO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has commenced an underwritten publ
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dos
IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis Tria
Read more →ATYRaTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Positive Data from a Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response of ATYR1923 in Pulmonary Sarcoidosis
Pangu’s basic and translational research in tRNA synthetase biology, conducted in collaboration with the Hong Kong University of Science and Technology, contributed to successful clinical proof-of-concept findings. aTyr Pharma Management to host conference call and webcast today
Read more →ATYRaTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis
Trial met primary endpoint, ATYR1923 was safe and well-tolerated. Efficacy observed in key endpoints including steroid reduction of 58% in the 5.0 mg/kg treatment group with 33% of patients in the group able to taper completely off of steroids. Clinically meaningful improvement
Read more →ATYRaTyr Pharma Announces Expansion of Research Collaboration with The Ohio State University
Collaboration led by Dr. Elliott Crouser to explore underlying cellular mechanisms of pulmonary sarcoidosis and identify potential sarcoidosis biomarkers. SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company, tod
Read more →ATYRaTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate Update
Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in mid-September 2021. Company to host conference call and webcast today, August 10th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LI
Read more →ATYRaTyr Pharma Announces Two Abstracts for ATYR1923 Accepted for Presentation at the European Respiratory Society International Congress
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that two abstracts for the company’s lead therapeutic cand
Read more →ATYRaTyr Pharma to Webcast Conference Call Reporting Second Quarter 2021 Financial Results
SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report second quarter 2021 financial results
Read more →ATYRaTyr Pharma Announces Grant of U.S. Patent for Use of Histidyl-tRNA Synthetase Fc Fusion Proteins for Reducing Inflammatory Response in the Lung
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Patent and Trademark Office (USPTO) has gran
Read more →ATYRaTyr Pharma Announces Last Patient Visit in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
Results from proof-of-concept study are expected in September 2021. SAN DIEGO, July 08, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today
Read more →ATYRaTyr Pharma to Host Virtual Key Opinion Leader Event on Current Treatment Options for Pulmonary Sarcoidosis
Event will feature Dr. Daniel Culver, Director of the Interstitial Lung Disease Program at the Cleveland Clinic. Conference call and webcast scheduled for Tuesday June 29th at 5:00pm ET/2:00pm PT. SAN DIEGO, June 23, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a
Read more →ATYRaTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody
Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2. aNRP2-14 blocks Semaphorin 3F/NRP2 signaling pathways which are implicated in immune-mediated diseases. SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- aTyr
Read more →ATYRaTyr Pharma Strengthens Board of Directors with Appointment of Dr. Sara Zaknoen
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Sara Zaknoen, M.D., to the company’s Boa
Read more →ATYRaTyr Pharma Presents Preclinical Research Highlighting Mechanistic Insights into Tumor Inhibitory Effects of ATYR2810
SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will present a poster and participate in a live Q&A
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces First Quarter 2021 Results and Provides Corporate Update Data from Phase 1
IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces First Quarter 2021 Results and Provides Corporate Update Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis e
Read more →ATYRaTyr Pharma Announces First Quarter 2021 Results and Provides Corporate Update
Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter. Preclinical data for IND candidate ATYR2810 showed anti-tumor effects in models of TNBC and NSCLC. Bispecific antibody project with subsidiary Pangu BioPharma achieved miles
Read more →ATYRaTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Achieve Milestones for First Year of Government Grant to Develop Bispecific Antibody Platform
SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company’s Hong Kong subsidiary, Pangu BioPharma Li
Read more →ATYRaTyr Pharma Announces Promotion of Leslie Nangle, Ph.D., to Vice President of Research
SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the promotion of Leslie Nangle, Ph.D., to Vice President, R
Read more →ATYRaTyr Pharma to Webcast Conference Call Reporting First Quarter 2021 Financial Results
SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report first quarter 2021 financial results an
Read more →ATYRaTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Steroids and Sarcoidosis
SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and the Foundation for Sarcoidosis Research (FSR), the leading internatio
Read more →ATYRaTyr Pharma and Lonza Announce Manufacturing Agreement for aTyr’s Anti-NRP2 Antibody ATYR2810
SAN DIEGO, April 14, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and Lonza today announced that the companies have entered into an agreeme
Read more →ATYRaTyr Pharma Presents Preclinical Research Showing Effects of ATYR2810 in Lung and Breast Cancer at the 2021 AACR Virtual Annual Meeting
Findings demonstrate tumor inhibitory effects of ATYR2810 when used as a monotherapy or in combination with chemotherapy in models of non-small cell lung cancer. ATYR2810 used in combination with chemotherapy or bevacizumab increased anti-tumor effects in triple-negative breast
Read more →ATYRaTyr Pharma Announces Co-Founder of the Foundation for Sarcoidosis Research and Leading Sarcoidosis Advocate Andrea Wilson as Patient Advisor
SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Andrea Wilson as a patient advisor to
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces Fourth Quarter and Full Year 2020 Results and Provides Corporate Update Co
IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces Fourth Quarter and Full Year 2020 Results and Provides Corporate Update Completed enrollment of ATYR1923 clinical trial in patients
Read more →ATYRaTyr Pharma Announces Fourth Quarter and Full Year 2020 Results and Provides Corporate Update
Completed enrollment of ATYR1923 clinical trial in patients with pulmonary sarcoidosis. Data is expected in the third quarter. Results from ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications demonstrated favorable safety profile and signals of act
Read more →ATYRaTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2020 Financial Results
SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report fourth quarter and full year 2020 fin
Read more →ATYRaTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications
Data provides first-in-patient mechanistic proof-of-concept for ATYR1923. ATYR1923 reduced key inflammatory cytokines that are implicated in sarcoidosis and other ILDs, consistent with findings from animal models. SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrat
IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Sev
Read more →ATYRaTyr Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting
SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present two posters at the upcoming
Read more →ATYRaTyr Pharma Announces New tRNA Synthetase Discovery Programs
Advancement of selected AARS and DARS fragments primarily targeting cancer Programs will accelerate discoveries initially focusing on natural killer (NK) cell biology SAN DIEGO , Feb. 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engag
Read more →ATYRaTyr Pharma to Present at BIO CEO & Investor Digital Conference
SAN DIEGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Exe
Read more →ATYRaTyr Pharma Presents Findings Further Validating NRP2 as a Potential Regulator of Solid Tumor Progression
Poster highlights NRP2 expression on immune cells in the tumor microenvironment. Company's lead NRP2 antibody, ATYR2810, is in development for oncology. SAN DIEGO, Jan. 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the disco
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Presents Findings Further Validating NRP2 as a Potential Regulator of Solid Tumor Pr
IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Presents Findings Further Validating NRP2 as a Potential Regulator of Solid Tumor Progression Poster highlights NRP2 expression on immune cell
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets fo
IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Synthetases Poster to be presented at
Read more →ATYRaTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Synthetases
Poster to be presented at the 2021 Society for Laboratory Automation and Screening Digital International Conference and Exhibition. Research approach led to the identification of target receptors for two tRNA synthetases and further validates company’s biology platform. SAN DIE
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Completes Subject Visits for Phas
IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Completes Subject Visits for Phase 1 Trial of ATYR1923 in Japan SAN DIEGO - January 14, 202
Read more →ATYRaTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Completes Subject Visits for Phase 1 Trial of ATYR1923 in Japan
SAN DIEGO, Jan. 14, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that its partner Kyorin Pharmaceutical Co., Ltd., or Kyori
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-
IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications Study me
Read more →ATYRaTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
Study met primary safety endpoint in moderate to severe hospitalized COVID-19 patients. A single dose of 3.0 mg/kg of ATYR1923 resulted in a median time to recovery of 5.5 days. 83% of patients receiving 3.0 mg/kg dose of ATYR1923 achieved recovery in less than a week. Managem
Read more →ATYRaTyr Pharma Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
SAN DIEGO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has completed the target enrollment in its Phase 1
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update Completes enrollm
IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com aTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update Completes enrollment of ATYR1923 clinical trial in patients with COVID
Read more →ATYRaTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update
Completes enrollment of ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications. Topline data is expected at turn of calendar year. Announces Investigational New Drug candidate in oncology, ATYR2810, from its NRP2 antibody program. Company to host con
Read more →ATYRaTyr Pharma Announces Publication in the Journal mAbs
Peer-reviewed paper supports aTyr’s antibody program. Research conducted in collaboration with AbCellera Biologics, Inc. SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovati
Read more →ATYRaTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline
Discovery advances the understanding of extracellular tRNA synthetase pathways. Findings may contribute to the development of new therapeutics to treat cancer and fibrosis. SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company
Read more →ATYRaTyr Pharma to Webcast Conference Call Reporting Third Quarter 2020 Financial Results - Management to host conference call and webcast on November 12th at 5:00 pm EST / 2:00 pm PST
SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report third quarter 2020 financial results a
Read more →ATYRaTyr Pharma Announces Research Collaboration with Medical University of South Carolina
Collaboration with leading expert Dr. Robert Gemmill will support the company’s neuropilin-2 (NRP2) antibody program in oncology. SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of
Read more →ATYRaTyr Pharma to Participate in ROTH Capital Partners Webinar on COVID-19 Therapeutics in Development on October 28th
SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Exe
Read more →ATYRaTyr Pharma Announces Completion of Enrollment in Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
Topline results are expected in the fourth quarter of 2020. Trial evaluating the preliminary safety and efficacy of ATYR1923 vs placebo has exceeded enrollment. SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in t
Read more →ATYRaTyr Pharma to Participate in October Virtual Investor Events
SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will participate in two upcoming virtual
Read more →ATYRaTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Doses First Subjects in Phase 1 Trial of ATYR1923 in Japan
SAN DIEGO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that its partner Kyorin Pharmaceutical Co., Ltd., or Kyor
Read more →ATYRaTyr Pharma Announces $20 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
Aspire Capital commits to purchase up to $20 Million of Common Stock over a period of up to 30 months. SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based
Read more →ATYRSCHEDULES Schedule 3(a) Subsidiaries Schedule 3(c) Capitalization Schedule 3(e) Conflicts Schedule 3(f) 1934 Act Filings Schedule 3(g) Material Changes Schedule 3(h) Litigation Schedule 3( j ) Intellectual Property Sched
COMMON STOCK PURCHASE AGREEMENT COMMON STOCK PURCHASE AGREEMENT (the "Agreement"), dated as of September 11, 2020, by and between ATYR PHARMA, INC., a Delaware corporation (the "Company"), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (the "Buyer"). Capital
Read more →ATYRaTyr Pharma to Present at September Investor Conferences
SAN DIEGO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will present at two investor conferen
Read more →ATYRaTyr Pharma to Present at Life Sciences Investor Forum on September 17th
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (the “Company”) (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay S. Shukla, M.D., M.S., Pre
Read more →ATYRaTyr Pharma Announces Second Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trial Programs
SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced second quarter results and provided a corporate update.
Read more →ATYRIMMEDIATE RELEASE Contact: Ashlee Dunston Investor Relations, aTyr Pharma adunston@atyrpharma.com aTyr Pharma Announces Second Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trial Programs Compan
IMMEDIATE RELEASE Contact: Ashlee Dunston Investor Relations, aTyr Pharma adunston@atyrpharma.com aTyr Pharma Announces Second Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trial Programs Company to host conference call and webcast today, August 1
Read more →ATYRaTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Proceeds to Phase 1 Trial of ATYR1923 in Japan
SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that its partner Kyorin Pharmaceutical Co., Ltd., or Ky
Read more →ATYRaTyr Pharma to Webcast Conference Call Reporting Second Quarter 2020 Financial Results
SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report second quarter 2020 financial resul
Read more →ATYRaTyr Pharma Presents Preclinical Research Showing NRP2 Antibody Effects in Triple-Negative Breast Cancer at the 2020 AACR Virtual Annual Meeting II
Poster details data from aTyr’s preclinical, domain specific Neuropilin-2 (NRP2) antibody program showing antibodies may increase sensitivity to chemotherapy in triple-negative breast cancer. SAN DIEGO, June 22, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a bioth
Read more →ATYRaTyr Pharma Highlights New Literature Implicating Neuropilin Pathway In SARS-CoV-2 Infection
Discovery that Neuropilin b1 domain acts as a binding site for SARS-CoV-2 Spike protein and aids viral entry. Lead therapeutic candidate, ATYR1923, modulates Neuropilin pathway to dampen inflammatory responses. SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nas
Read more →ATYRaTyr Pharma Announces Dosing of First Patient in Phase 2 Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has dosed the first patient in a Phase 2 study
Read more →ATYRaTyr Pharma to Present Poster at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
SAN DIEGO, May 20, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will present an abstract in a poster session at
Read more →ATYRaTyr Pharma Announces First Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trials in Pulmonary Sarcoidosis and COVID-19
SAN DIEGO, May 12, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced first quarter results and provided a corporate update.
Read more →ATYRIMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces First Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trials in
IMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces First Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trials in Pulmonary Sarcoidosis and COVID-19 Company to host c
Read more →ATYRaTyr Pharma to Webcast Conference Call Reporting First Quarter 2020 Financial Results
SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report first quarter 2020 financial results
Read more →ATYRaTyr Pharma Announces Publication of Two Abstracts in American Journal of Respiratory and Critical Care Medicine
Abstracts originally accepted for presentation at the 2020 American Thoracic Society (ATS) International Conference Findings confirm that aTyr’s lead clinical candidate, ATYR1923, selectively binds to Neuropilin-2 (NRP2), a unique target expressed on key immune cells in inflamma
Read more →ATYRIMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces Phase 2 Study of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications Fo
IMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces Phase 2 Study of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications Following FDA Acceptance of IND Application SAN DIEGO -
Read more →ATYRaTyr Pharma Announces Phase 2 Study of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications Following FDA Acceptance of IND Application
SAN DIEGO, April 21, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the U.S. Food and Drug Administration (FDA) has a
Read more →ATYRIMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces Fourth Quarter and Full Year 2019 Results and Provides Corporate Update Company to host
IMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces Fourth Quarter and Full Year 2019 Results and Provides Corporate Update Company to host conference call and webcast today at 5:00 p.m. EDT /
Read more →ATYRaTyr Pharma Announces Fourth Quarter and Full Year 2019 Results and Provides Corporate Update
Company to host conference call and webcast today at 5:00 p.m. EDT / 2:00 p.m. PDT SAN DIEGO, March 26, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunologi
Read more →ATYRaTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Government Grant to Fund Bispecific Antibody Development Platform
Grant awarded by the Hong Kong Government's Innovation and Technology Commission under the Partnership Research Program Two-year project will initially focus on development of new bi-specific antibodies targeting NRP2 SAN DIEGO, March 24, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, I
Read more →ATYRaTyr Pharma to Announce Fourth Quarter and Full Year End 2019 Financial Results on March 26th
SAN DIEGO, March 19, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report fourth quarter and full year 2020
Read more →ATYRaTyr Pharma Announces Exercise and Closing of Over-Allotment Option in Public Offering
SAN DIEGO, March 10, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the underwriters of its previously announced public of
Read more →ATYRaTyr Pharma Announces Publication in the Journal Cellular and Molecular Immunology
Paper highlights the essential role that histidyl tRNA synthetase (HARS) plays in immune responses in a broad range of inflammatory disease states Lead therapeutic candidate, ATYR1923, being evaluated in a Phase 1b/2a trial in patients with pulmonary sarcoidosis SAN DIEGO, Feb.
Read more →ATYRaTyr Pharma Announces Pricing of $18 million Underwritten Public Offering
SAN DIEGO, Feb. 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the pricing of an underwritten public offering of 4,235
Read more →ATYRaTyr Pharma Announces Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of ATYR1923 in Japan
aTyr eligible to receive up to $175 million in total payments, including $8 million upfront, plus tiered sales royalties Kyorin to fund all ATYR1923 development and commercialization activities in Japan SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIF
Read more →ATYRIMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercializ
IMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of ATYR1923 in Japan aTyr eligible to receive u
Read more →ATYRaTyr Pharma Announces Positive Interim Safety Results from Ongoing Phase 1b/2a Clinical Trial of ATYR1923
ATYR1923 safe and well tolerated in initial 15 randomized patients with pulmonary sarcoidosis No drug-related serious adverse events observed SAN DIEGO, Dec. 12, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and de
Read more →ATYRIMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces Positive Interim Safety Results from Ongoing Phase 1b/2a Clinical Trial of ATYR1923 ATY
IMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces Positive Interim Safety Results from Ongoing Phase 1b/2a Clinical Trial of ATYR1923 ATYR1923 safe and well tolerated in initial 15 randomize
Read more →ATYRaTyr Pharma Announces Third Quarter 2019 Results and Provides Corporate Update
Interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients due in December 2019 Company to host conference call and webcast today, November 14, at 5:00pm EDT SAN DIEGO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq
Read more →ATYRIMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces Third Quarter 2019 Results and Provides Corporate Update Interim safety results from Ph
IMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces Third Quarter 2019 Results and Provides Corporate Update Interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmo
Read more →ATYRaTyr Pharma to Present at the Stifel Healthcare Conference 2019
SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Dr. Sanjay Shukla, President and Chief Executive O
Read more →ATYRaTyr Pharma to Announce Third Quarter Results on November 14th
SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report third quarter 2019 results after th
Read more →ATYRaTyr Pharma Announces Research Collaboration with Boston Children’s Hospital
SAN DIEGO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company has entered into a research collaborat
Read more →ATYRaTyr Pharma to Participate in September Conferences
SAN DIEGO, Sept. 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will be participating in two investor
Read more →ATYRaTyr Pharma to Present at the H.C. Wainwright 21st Annual Global Investment Conference
SAN DIEGO, Sept. 04, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief
Read more →ATYRaTyr Pharma Announces Second Quarter 2019 Results and Provides Corporate Update
aTyr to report interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients in Q4 2019 Company to host conference call and webcast today, August 14, at 5:00pm EDT SAN DIEGO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nas
Read more →ATYRIMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces Second Quarter 2019 Results and Provides Corporate Update aTyr to report interim safety
IMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces Second Quarter 2019 Results and Provides Corporate Update aTyr to report interim safety results from Phase 1b/2a proof-of-concept trial of A
Read more →ATYRaTyr Pharma to Announce Second Quarter 2019 Results on August 14th
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report second quarter 2019 results after t
Read more →ATYRaTyr Pharma to Host Key Opinion Leader Call and Webcast on Sarcoidosis and the Current Treatment Landscape
SAN DIEGO, July 10, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will host a Key Opinion Leader (KOL) call
Read more →ATYRaTyr Pharma Strengthens Board of Directors with the Appointment of Two New Members
SAN DIEGO, July 01, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointments of Jane Gross, Ph.D. and Svetlana Lucas,
Read more →ATYRIMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Strengthens Board of Directors with the Appointment of Two New Members
IMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Strengthens Board of Directors with the Appointment of Two New Members SAN DIEGO - July 1, 2019 - aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics
Read more →ATYRaTyr Pharma Announces Reverse Stock Split to Regain NASDAQ Compliance
SAN DIEGO, June 28, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that its Board of Directors has approved a one-for-14 reve
Read more →ATYRIMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces Reverse Stock Split to Regain NASDAQ Compliance
IMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces Reverse Stock Split to Regain NASDAQ Compliance SAN DIEGO - June 28, 2019 - aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company enga
Read more →ATYRaTyr Pharma Announces First Quarter 2019 Results and Provides Corporate Update
Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients ongoing Advanced lead position in Neuropilin-2 (NRP-2) biology with inaugural NRP-2 summit Company to host conference call and webcast today at 5:00pm EDT / 2:00 PDT SAN DIEGO, May 13, 20
Read more →ATYRIMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces First Quarter 2019 Results and Provides Corporate Update Phase 1b/2a proof-of-concept c
IMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces First Quarter 2019 Results and Provides Corporate Update Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis pa
Read more →ATYRaTyr Pharma to Announce First Quarter 2019 Results on May 13th
SAN DIEGO, May 06, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report first quarter 2019 results after the
Read more →ATYRaTyr Pharma to Host Inaugural Summit Meeting on Neuropilin-2 (NRP-2) Biology
SAN DIEGO, April 16, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the Company will host a summit meeting on Neuropi
Read more →ATYRIMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces $5 Million Registered Direct Offering led by The Federated Kaufmann Small Cap Fund
IMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces $5 Million Registered Direct Offering led by The Federated Kaufmann Small Cap Fund SAN DIEGO - April 11, 2019 - aTyr Pharma, Inc. (Nasdaq: L
Read more →ATYRaTyr Pharma Announces $5 Million Registered Direct Offering led by The Federated Kaufmann Small Cap Fund
SAN DIEGO, April 11, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a definitive agreement with T
Read more →ATYRaTyr Pharma to Present Poster at the American Thoracic Society 2019 International Conference
SAN DIEGO, April 08, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the Company will present an abstract in a poster
Read more →ATYRIMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces Fourth Quarter and Full Year 2018 Results and Provides Corporate Update Phase 1b/2a pro
IMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Announces Fourth Quarter and Full Year 2018 Results and Provides Corporate Update Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary
Read more →ATYRaTyr Pharma Announces Fourth Quarter and Full Year 2018 Results and Provides Corporate Update
Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients initiated in December 2018 First tRNA synthetase partnership announced in March 2019 SAN DIEGO, March 25, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics compa
Read more →ATYRaTyr Pharma Announces Poster Presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting
SAN DIEGO, March 21, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that data from its successful pilot study with the Uni
Read more →ATYRaTyr Pharma to Announce Fourth Quarter and Full Year 2018 Financial Results on March 25th
SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report fourth quarter and full year 2018
Read more →ATYRCorporate Presentation March 2019 Forward-Looking Statements The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform A
Translating New Immune Pathways into Meaningful Medicines NASDAQ: LIFE Exhibit 99.1 Corporate Presentation March 2019 Forward-Looking Statements The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Secur
Read more →ATYRaTyr Pharma Announces Research Collaboration With Global Biotherapeutics Leader CSL Behring
Partnership to accelerate development of IND candidates from tRNA synthetases in aTyr’s pipeline aTyr eligible to receive up to $17 million in potential option fees SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged
Read more →ATYRaTyr Pharma Announces Participation at March Investor Conferences
SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that management will provide an update on the ongoing
Read more →ATYRIMMEDIATE RELEASE Contact: Joyce Allaire Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Presents Compelling Preclinical Data Highlighting Potential of ATYR1923 to Regulate Myeloid Cell
Managing Director, LifeSci Advisors, LLC jallaire@lifesciadvisors.com aTyr Pharma Presents Compelling Preclinical Data Highlighting Potential of ATYR1923 to Regulate Myeloid Cell Biology During Lung Inflammation Poster presentation at the Keystone Symposia 2019 Conference: Mye
Read more →ATYRaTyr Pharma Presents Compelling Preclinical Data Highlighting Potential of ATYR1923 to Regulate Myeloid Cell Biology During Lung Inflammation
SAN DIEGO, Feb. 27, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a poster presentation at the Keystone Symposia 2019 Con
Read more →ATYRaTyr Pharma to Present at the BIO CEO & Investor Conference
SAN DIEGO, Feb. 05, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief
Read more →ATYRaTyr Pharma Announces Research Collaboration with the University of Nebraska Medical Center and Expansion of Successful Pilot Study
Collaboration to advance neuropilin-2 biology and explore potential therapeutic opportunities for ATYR1923 Reinforces aTyr’s commitment to working with a strategic network of leading academic collaborators SAN DIEGO, Jan. 30, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:
Read more →ATYRaTyr Pharma Announces Participation at Upcoming San Francisco Investor Events
SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that management will provide an update on the ongoing c
Read more →ATYRaTyr Pharma Announces Initiation of Phase 1b/2a Study of ATYR1923 in Patients with Pulmonary Sarcoidosis and Collaboration with the Foundation for Sarcoidosis Research (FSR)
SAN DIEGO, Dec. 04, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the initiation of a Phase 1b/2a study evaluating its le
Read more →ATYRaTyr Pharma to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
SAN DIEGO, Nov. 28, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay Shukla, M.D., M.S., president and chief exe
Read more →ATYRIMMEDIATE RELEASE Contact: Jason Spark Managing Director, Canale Communications Inc jason@canalecomm.com 6 19-849-6005 aTyr Pharma Announces Third Quarter 2018 Operating Results and Provides Corporate Update - Initiation
IMMEDIATE RELEASE Contact: Jason Spark Managing Director, Canale Communications Inc jason@canalecomm.com 6 19-849-6005 aTyr Pharma Announces Third Quarter 2018 Operating Results and Provides Corporate Update - Initiation of Proof-of-Concept Study in Patients with Pulmonar
Read more →ATYRaTyr Pharma Announces Third Quarter 2018 Operating Results and Provides Corporate Update
- Initiation of Proof-of-Concept Study in Patients with Pulmonary Sarcoidosis Planned for Fourth Quarter of 2018 - - Conference Call Today at 5:00 p.m. ET / 2:00 p.m. PT – SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company e
Read more →ATYRaTyr Pharma to Host Conference Call and Webcast of Third Quarter 2018 Financial Results on November 13, 2018
SAN DIEGO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report its third quarter financial results
Read more →ATYRaTyr Pharma Presents at American Society of Human Genetics 2018 Meeting
SAN DIEGO, Oct. 17, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a presentation at the American Society of Human Genetic
Read more →ATYRIMMEDIATE RELEASE Contact: Jason Spark Managing Director, Canale Communications Inc. jason@canalecomm.com 6 19-849-6005 aTyr Pharma Announces Leadership Transition
IMMEDIATE RELEASE Contact: Jason Spark Managing Director, Canale Communications Inc. jason@canalecomm.com 6 19-849-6005 aTyr Pharma Announces Leadership Transition SAN DIEGO - October 15, 2018 - aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the di
Read more →ATYRaTyr Pharma Announces Leadership Transition
SAN DIEGO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the resignation of David J. King, Ph.D. as Chief Scient
Read more →ATYRaTyr Pharma Announces Pulmonary Sarcoidosis as Disease Indication for Phase 1b/2a Clinical Study and Educational Webinar
SAN DIEGO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has selected pulmonary sarcoidosis as the dise
Read more →ATYRaTyr Pharma to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference
SAN DIEGO, Sept. 20, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay Shukla, M.D., M.S., president and chief ex
Read more →ATYRaTyr Pharma to Present at the Baird 2018 Global Healthcare Conference
SAN DIEGO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay Shukla, M.D., M.S., president and chief exec
Read more →ATYRIMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces Second Quarter 2018 Operating Results and Provides Corporate Update - Conference Call To
IMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces Second Quarter 2018 Operating Results and Provides Corporate Update SAN DIEGO - August 14, 2018 - aTyr Pharma, Inc. (Nasdaq: LIFE), a biothe
Read more →ATYRaTyr Pharma Announces Second Quarter 2018 Operating Results and Provides Corporate Update
SAN DIEGO , Aug. 14, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced operating results for the second quarter ended June 30
Read more →ATYRaTyr Pharma to Host Conference Call and Webcast of Second Quarter 2018 Financial Results on August 14, 2018
SAN DIEGO, Aug. 08, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report its second quarter financial result
Read more →ATYRaTyr Pharma Appoints Jill Broadfoot as Chief Financial Officer
SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Jill Broadfoot has joined aTyr as Chief Financial
Read more →ATYRaTyr Pharma Presents Positive Lung and Skin Findings with ATYR1923 in a Translational Animal Model at the Scleroderma Foundation National Patient Education Conference
SAN DIEGO, July 26, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a poster presentation at the Scleroderma Foundation Nat
Read more →ATYRIMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Presents Positive Lung and Skin Findings with ATYR1923 in a Translational Animal Model at the Scle
IMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Presents Positive Lung and Skin Findings with ATYR1923 in a Translational Animal Model at the Scleroderma Foundation National Patient Education Confer
Read more →ATYRaTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate
ATYR1923 Well-Tolerated at all Doses Tested, with No Significant Adverse Events Pharmacokinetic Profile Supports Potential Once-Monthly Dosing SAN DIEGO, June 26, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and de
Read more →ATYRIMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate ATYR1923 Well-Tolerated at all
Sr. Director, Investor Relations mjohnson@atyrpharma.com aTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate ATYR1923 Well-Tolerated at all Doses Tested, with No Significant Adverse Events Pharmacokinetic Profile Supports Potential Once-Monthly Dosi
Read more →ATYRaTyr Pharma to Present at Jefferies 2018 Global Healthcare Conference
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay Shukla, M.D., M.S., President and Chief Execu
Read more →ATYRaTyr Pharma Presents Poster on Preclinical Data from ATYR1923 Program at American Thoracic Society 2018 International Conference
SAN DIEGO, May 17, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a poster presentation at the American Thoracic Society (A
Read more →ATYRIMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces First Quarter 2018 Operating Results, Program Prioritization and Corporate Restructuring
IMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces First Quarter 2018 Operating Results, Program Prioritization and Corporate Restructuring -Conference Call Today at 8:00 am E.T./5:00 a.m. P
Read more →ATYRaTyr Pharma Announces First Quarter 2018 Operating Results, Program Prioritization and Corporate Restructuring
SAN DIEGO, May 14, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced operating results for the first quarter ended March 31, 2
Read more →ATYRaTyr Pharma to Host Conference Call and Webcast of First Quarter 2018 Financial Results on May 14, 2018
SAN DIEGO, May 08, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report its first quarter financial results o
Read more →ATYRaTyr Pharma Provides Mechanistic Update on Resokine Pathway at American Academy of Immunology Annual Meeting
SAN DIEGO, May 02, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a poster presentation at the American Academy of Immunolo
Read more →ATYRaTyr Pharma Announces Fourth Quarter and Year-End 2017 Operating Results and Provides Corporate Update
SAN DIEGO, March 19, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced operating results for the fourth quarter and year ended
Read more →ATYRIMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces Fourth Quarter and Year-End 2017 Operating Results and Provides Corporate Update - Confe
IMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces Fourth Quarter and Year-End 2017 Operating Results and Provides Corporate Update SAN DIEGO - March 19, 2018 - aTyr Pharma, Inc. (Nasdaq: LIF
Read more →ATYRaTyr Pharma to Host Conference Call and Webcast of Full Year 2017 Financial Results on March 19, 2018
SAN DIEGO, March 07, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report its year end 2017 financial results
Read more →ATYRaTyr Pharma to Present at Two Upcoming Investor Conferences in March
SAN DIEGO, March 01, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced its participation at two investor conferences in March:
Read more →ATYRIdentification of Novel Liquid Biopsy Biomarker for Monitoring the Immune Set Point in Both Solid Tumor and Hematological Malignancy Patients Ryan Adams, Elisabeth Mertsching, Leslie Nangle, Kathy Ogilvie, Andrea Cubitt,
Introduction A number of non-canonical functions of proteins generated from tRNA synthetase genes have been reported, demonstrating diverse roles for these proteins outside of protein synthesis. These include roles in regulating inflammatory responses, angiogenesis and mTOR signa
Read more →ATYRaTyr Pharma to Present at the 36th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay Shukla, M.D., M.S., President and Chief Exec
Read more →ATYRaTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium
SAN DIEGO, Dec. 21, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat patients suffering from rare, severe, immune-mediated diseases, as well as various c
Read more →ATYRaTyr Pharma to Participate at the BMO Prescriptions for Success Healthcare Conference
SAN DIEGO, Dec. 07, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat patients suffering from rare, severe, immune-mediated diseases, as well as various c
Read more →ATYRaTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923)
– Second Physiocrine-based therapeutic candidate enters the clinic – – Top-line data expected in 2Q 2018 – – iMod.Fc (ATYR1923) to target interstitial lung diseases with an immune component – SAN DIEGO, Nov. 27, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a bioth
Read more →ATYRaTyr Pharma to Participate at the Piper Jaffray 29th Annual Healthcare Conference
SAN DIEGO, Nov. 21, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat patients suffering from rare, severe, immune-mediated diseases, as well as various c
Read more →ATYRaTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update
- Initiation of Phase 1 clinical trial of iMod.Fc on-track for this quarter - - Selection of antibody for ORCA program on-track for this quarter - SAN DIEGO, Nov. 14, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery an
Read more →ATYRIMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update - Initiation of Phase
IMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update - Initiation of Phase 1 clinical trial of iMod.Fc on-track for this quar
Read more →ATYRIMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces Leadership Transition - Dr. John Mendlein Transitions from CEO to Non-Executive Board Me
IMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces Leadership Transition SAN DIEGO - November 1, 2017 - aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery an
Read more →ATYRaTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle Society
SAN DIEGO, Sept. 27, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immunology-based therapeutics, harnessing new pathway insights from human Physiocrine proteins, to treat patients suffering from se
Read more →ATYRaTyr Pharma to Present at Two Upcoming Investor Conferences in September
SAN DIEGO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immunology-based therapeutics, harnessing new pathway insights from human Physiocrine proteins, to treat patients suffering from se
Read more →ATYRaTyr Pharma Announces $45 Million Equity Financing
SAN DIEGO, Aug. 28, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics, harnessing the Resokine pathway, to treat patients suffering from severe, rare immune-mediated disea
Read more →ATYRIMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces $45 Million Equity Financing
Exhibit 99.1 IMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces $45 Million Equity Financing SAN DIEGO - August 28, 2017 - aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged
Read more →ATYRIMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pi
IMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline - Resolaris Demonstrated Favorable Safety Pr
Read more →ATYRaTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline
– Resolaris Demonstrated Favorable Safety Profile in Rare Muscular Dystrophy Patients in Extension Studies – – iMod.Fc Program for Interstitial Lung Disease (ILD) on Track to Commence Phase 1 Clinical Trial – – Project ORCA: Leverages a New Immuno-Oncology Antibody Target Based
Read more →ATYRaTyr Pharma Announces Date of Earnings Release For Second Quarter 2017 Financial Results
SAN DIEGO, Aug. 10, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, will report its financial results for the second quarter 2017 after
Read more →ATYRIMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces Date of Earnings Release For Second Quarter 2017 Financial Results
IMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces Date of Earnings Release For Second Quarter 2017 Financial Results SAN DIEGO - August 10, 2017 - aTyr Pharma, Inc. (Nasdaq: LIFE), a biother
Read more →ATYRaTyr Pharma to Present at Jefferies 2017 Global Healthcare Conference
SAN DIEGO, May 31, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the Company's participation at the Jefferies 2017 Gl
Read more →ATYRaTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the American Thoracic Society 2017 International Conference and Will Host an Educational Webinar
- Poster Presentations to Explore Potential of Augmenting Resokine Pathway in Severe, Rare Pulmonary Diseases with an Immune or Fibrotic Component - - Conference Call and Webcast Featuring Guest Speaker Dr. Steven Nathan on May 23, 2017 at 8:30 am ET - SAN DIEGO, May 15, 2017 (
Read more →ATYRaTyr Pharma Announces First Quarter 2017 Operating Results
– Announced Promising Top-Line Results from ResolarisTM Phase 1b/2 Trial in Early Onset FSHD – – Preclinical Data from StalarisTM Program to be Presented at American Thoracic Society International Conference in May 2017 – – aTyr Pharma to Host Educational Webinar on Stalaris Pr
Read more →ATYRIMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces First Quarter 2017 Operating Results - Announced Promising Top-Line Results from Resolar
IMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces First Quarter 2017 Operating Results - Announced Promising Top-Line Results from Resolaris TM Phase 1b/2 Trial in Early Onset FSHD - - Precl
Read more →ATYRaTyr Pharma Announces Promising Top-Line Results from Resolaris™ Phase 1b/2 Clinical Trial in Patients with Early Onset Facioscapulohumeral Muscular Dystrophy
- 63% of Patients Observed Increased Muscle Strength - - Resolaris Demonstrated a Generally Well-Tolerated Safety Profile in Younger Patient Population - SAN DIEGO, April 24, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the disc
Read more →ATYRaTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting
- Resolaris Demonstrated Favorable Safety Profile and Promising Signals of Clinical Activity - - Resolaris has FDA Fast Track and Orphan Drug Designation for Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) - SAN DIEGO, April 24, 2017
Read more →ATYRIMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B
IMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the Am
Read more →ATYRaTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors
SAN DIEGO, April 10, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the appointment of Timothy P. Coughlin to its boar
Read more →ATYRaTyr Pharma to Present at Needham and Company 16th Annual Healthcare Conference
SAN DIEGO, March 29, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the Company’s presentation at the Needham and Comp
Read more →ATYRIMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces Fourth Quarter and Year-End 2016 Operating Results - Resolaris TM , in multiple rare myo
IMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces Fourth Quarter and Year-End 2016 Operating Results - Resolaris TM , in multiple rare myopathy indications in four clinical trials in 2016, d
Read more →ATYRIMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com +1-858-223-1163 aTyr Pharma Reports Promising Signals of Clinical Activity in Multiple Rare Genetically Distinct Myopathies
IMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com +1-858-223-1163 aTyr Pharma Reports Promising Signals of Clinical Activity in Multiple Rare Genetically Distinct Myopathies with Resolaris in Exploratory Trials - Improved Mu
Read more →ATYRIMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces Third Quarter 2016 Operating Results - Data Readouts from Three Clinical Trials of Resol
IMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces Third Quarter 2016 Operating Results SAN DIEGO - November 14, 2016 - aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in
Read more →ATYRlife-ex991_110.pptx.htm New Hope For Severe Rare Muscle & Lung Disease Patients Building a New Class of Medicines Physiocrine Based Therapeutics To Promote Tissue Homeostasis Corporate Presentation November 2016 Forward-
New Hope For Severe Rare Muscle & Lung Disease Patients Building a New Class of Medicines Physiocrine Based Therapeutics To Promote Tissue Homeostasis Corporate Presentation November 2016 Forward-Looking Statements The following slides and any accompanying oral presentation cont
Read more →ATYRIMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Presents Additional Data for Resolaris Phase 1b/2 Trial in Adult Patients with Facioscapulohumeral
IMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Presents Additional Data for Resolaris Phase 1b/2 Trial in Adult Patients with Facioscapulohumeral Muscular Dystrophy at the 21st International Annual
Read more →ATYRIMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces Second Quarter 2016 Operating Results - On Track to Announce Data from Three Clinical Tr
IMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163 aTyr Pharma Announces Second Quarter 2016 Operating Results - On Track to Announce Data from Three Clinical Trials for Resolaris in Rare Genetic Muscle Diseases i
Read more →ATYRIMMEDIATE RELEASE Contact: Mark Johnson Jessica Rowlands Sr. Director, Investor Relations Feinstein Kean Healthcare mjohnson@atyrpharma.com jessica.rowlands@fkhealth.com 858-223-1163 202-729-4089 aTyr Pharma Announces Fi
IMMEDIATE RELEASE Contact: Mark Johnson Jessica Rowlands Sr. Director, Investor Relations Feinstein Kean Healthcare mjohnson@atyrpharma.com jessica.rowlands@fkhealth.com 858-223-1163 202-729-4089 aTyr Pharma Announces First Quarter 2016 Operating Results Company Continues Dev
Read more →ATYRlife-ex991_110.pptx.htm Building a New Class of Medicines - Physiocrine Based Therapeutics 1st Rare Disease Trial Completed - New Hope for Muscular Dystrophy Patients April 2016 Forward-Looking Statements The following s
Building a New Class of Medicines - Physiocrine Based Therapeutics 1st Rare Disease Trial Completed - New Hope for Muscular Dystrophy Patients April 2016 Forward-Looking Statements The following slides and any accompanying oral presentation contain forward-looking statements wit
Read more →ATYRIMMEDIATE RELEASE Contact: Sanuj K. Ravindran, MD and Jessica Rowlands Chief Business Officer Feinstein Kean Healthcare sravindran@atyrpharma.com jessica.rowlands@fkhealth.com 858-223-1163 202-729-4089 aTyr Pharma Announ
IMMEDIATE RELEASE Contact: Sanuj K. Ravindran, MD and Jessica Rowlands Chief Business Officer Feinstein Kean Healthcare sravindran@atyrpharma.com jessica.rowlands@fkhealth.com 858-223-1163 202-729-4089 aTyr Pharma Announces Fourth Quarter 2015 Operating Results Company Contin
Read more →ATYRlife-ex991_6.pptx.htm New Promise for Rare Disease Patients with Immune & Fibrotic Pathologies January 2016 Forward-Looking Statements The following slides and any accompanying oral presentation contain forward-looking s
New Promise for Rare Disease Patients with Immune & Fibrotic Pathologies January 2016 Forward-Looking Statements The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1
Read more →ATYRIMMEDIATE RELEASE Contact: Marcy Graham Jessica Rowlands Vice President, Investor Relations & Corporate Communications Feinstein Kean Healthcare mgraham@atyrpharma.com jessica.rowlands@fkhealth.com 858-223-1163 202-729-4
IMMEDIATE RELEASE Contact: Marcy Graham Jessica Rowlands Vice President, Investor Relations & Corporate Communications Feinstein Kean Healthcare mgraham@atyrpharma.com jessica.rowlands@fkhealth.com 858-223-1163 202-729-4089 aTyr Pharma Announces Third Quarter 2015 Operating Re
Read more →ATYRMarcy Graham Jessica Rowlands Vice President, Investor Relations & Corporate Communications Feinstein Kean Healthcare mgraham@atyrpharma.com jessica.rowlands@fkhealth.com 858-223-1163 202-7
Marcy Graham Jessica Rowlands Vice President, Investor Relations & Corporate Communications Feinstein Kean Healthcare mgraham@atyrpharma.com jessica.rowlands@fkhealth.com 858-223-1163 202-729-4089 ATYR PHARMA ANNOUNCES TRANSITIONS IN CLINICAL DEVELOPMENT & OPERATIONS SAN DI
Read more →ATYRMarcy Graham Jessica Rowlands Vice President, Investor Relations & Corporate Communications mgraham@atyrpharma.com 858-223-1163 Feinstein Kean Healthcare jessica.rowlands@fkhealth.com 202-7
Contact: Marcy Graham Jessica Rowlands Vice President, Investor Relations & Corporate Communications mgraham@atyrpharma.com 858-223-1163 Feinstein Kean Healthcare jessica.rowlands@fkhealth.com 202-729-4089 ATYR PHARMA ANNOUNCES CHANGE IN LEADERSHIP SAN DIEGO July 13, 2015 a
Read more →Competitive Position
How ATYR ranks across every disease it competes inCompetitive Position is a premium feature
See how ATYR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial